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Introduction: Vitamin K antagonists (VKA) are historically used to treat thrombosis but 
newer direct acting oral anticoagulants (DOAC) have been released. DOACs influence 
laboratory methods that monitor haemostasis, leading to false positives and prolonged 
clotting results. Trough DOAC concentrations may have less influence at than at peak, 
but this is unknown. There is speculation that obesity also affects DOAC efficiency. 
This study sought to validate the effects of two common DOACs, rivaroxaban and 
apixaban, on 12 laboratory assays at peak and trough concentrations, as well as the 
influence of obesity on the drugs and assays. Methods: Rivaroxaban (n=20) and 
apixaban (n=21) patients had samples collected immediately before their next dose, 
and 3 hours after to provide peak and trough. Healthy controls (n=20) provided a 
sample at one-time point. Relevant medical histories and demographics, including BMI, 
were collected after obtaining informed consent. Samples underwent coagulation and 
thrombophilia panels as well as thrombin antithrombin complex, prothrombin fragments 
1+2, and thrombin generation assays (TGA). Statistical analysis was performed 
between peak and controls, peak and trough, and all BMI groups. Results: Significant 
prolongations were found with the prothrombin time (PT), activated partial 
thromboplastin time (APTT), TGA, and false positives for the dilute Russell viper 
venom time (DRVVT) by both rivaroxaban and apixaban. Apixaban was less potent 
than rivaroxaban with significant differences only between peak and trough for PT, and 
APTT. Only two results were influenced by weight; the APTT with rivaroxaban and free 
protein S for the controls. Conclusion: Rivaroxaban and apixaban are similar drugs but 
impact the assays differently due to dosage, half-life, and rate activity. Both influence 
assays more at peak than trough, but trough is still notably influenced compared to the 
controls. This study highlights the influence of these drugs on most tests performed in a 
haemostasis laboratory. 
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1.1 Introduction to Coagulation 
1.1.1. Primary Haemostasis  
Primary haemostasis is characterised by the formation of an aggregate platelet plug which 
begins as soon as endothelial tissue is damaged or exposed. The aggregation of platelets occurs 
from the binding of endothelial von Willebrand factor to collagen, which then binds and 
activates platelets. Further, fibrinogen circulating within the plasma binds to activated platelets 
and forms a soft platelet plug that is reinforced from insoluble fibrin generated from secondary 
haemostasis (1). 
1.1.2 Secondary Haemostasis, and Fibrinolysis. 
Secondary haemostasis was described in 1964 as a coagulation cascade, which was initiated 
after activation of either the extrinsic (initiated by tissue factor) or intrinsic (initiated by contact 
factors) pathways, leading to the activation of the common pathway (2,3). The extrinsic pathway 
begins with exposed tissue factor from trauma reacting with Factor VII (FVII) and calcium ions to 
activate Factor X (FX). The intrinsic pathway begins when Factor XII (FXII) is activated via contact 
with negatively charged surfaces. FXIIa then activates Factor XI (FXI) which in turn activates 
Factor IX (FIX) leading to FX activation with Factor VIII as a cofactor, phospholipids, and calcium 
ions. Both intrinsic and extrinsic pathways activate the common pathway which begins with the 
activation of FX with Factor V as a co-factor which cleaves prothrombin into thrombin. Thrombin 
then cleaves fibrinogen into fibrin and forms fibrin monomers, and then a fibrin based gel. 
Thrombin also activates FXIII which interacts with the fibrin gel to form the stable fibrin clot, a 
series of crosslinked polymers that prevents further bleeding (4).                                                    . 
Whilst the traditional coagulation cascade is useful for the evaluation of coagulation assay 
results, the model is no longer the most physiologically accurate model for coagulation (5). The 
simple biochemical pathway does not take in account the presence of anticoagulant proteins 
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such as protein C and tissue factor pathway inhibitor, the interactions of the fibrinolysis 
pathways, or the interactions of both intrinsic and extrinsic pathways on each other. A cell based 
model of the coagulation cascade has become the current gold standard for our understanding 
of in vivo blood coagulation with initiation, amplification, and termination phases providing 
coagulation. Initiation begins with vascular endothelium and circulating blood cells being 
disturbed by trauma or disease revealing cellular bound tissue factor. This tissue factor interacts 
with plasma derived FVIIa which activates lesser amounts of FIXa and FXa, with the cofactor FVa, 
to produce the prothrombinase complex. The prothrombinase complex cleaves prothrombin 
into active thrombin and leads to the amplification phase. Active thrombin binds to platelets 
previously activated from primary haemostasis, as well as propagate and activate the release of 
Factors XI, IX, VIII, and V from internal platelet stores (6).  The activated FIX and FVIII leads to 
the formation of the tenase complex in copious quantities. Large numbers of factors migrate to 
the surface of platelets and produce the rapid formation of prothrombinase and the generation 
of a large thrombin burst. Thrombin then cleaves fibrinogen to fibrin monomers and forms the 
fibrin clot (7).  
1.1.3. Regulation of Coagulation. 
Termination is the last phase of coagulation and is regulated by anticoagulant feedback 
mechanisms which inhibit the proteins and cease the formation of the clot. Thrombin is 
regulated by thrombomodulin, a protein co-factor in activating the anticoagulant protein C, 
catalysed by protein S. Activated protein C proteolytically cleaves peptide bonds in FVa and 
FVIIIa, the critical precursors in generating thrombin, causing the inactivation of both factors, 
and inhibiting further thrombin generation and coagulation. Antithrombin, a protein produced 
in the liver inhibits factors Xa, IXa, XIa, XIIa and thrombin. The final regulatory protein is tissue 
factor pathway inhibitor (TFPI), a single chain polypeptide that binds to FVIIa within a tissue 
factor:FVIIa complex, FXa and FV and to FVa when present in the  prothrombinase complex. The 
inhibition of these factors by TFPI serve to prevent the conversion of prothrombin to thrombin 
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during the initiation phase of coagulation. Without these key mechanisms in place the cascade 
will produce excessive generation of thrombin and fibrin, which will significantly increase the 
chances of developing unnecessary clotting events known as thrombosis.  
 
1.2. What is Thrombosis? 
1.2.1. Global Burden of Thrombosis 
Thrombosis is a condition characterised by the formation of blood clots within the vascular 
system of a living animal. These obstructions of blood vessels can also lead to stroke, myocardial 
infarction, foetal wastage syndrome and localised ischemia within individual organs or limbs (9). 
Thrombosis is most noticeable when occurring within deep veins around the pelvic region or 
inner legs which is named Deep Vein Thrombosis (DVT) (10), or within a major artery which can 
lead to ischemia and tissue necrosis from vessel occlusion and platelet aggregation (11). Thrombi 
within vessels can be dislodged and block smaller vessels throughout the body in an event called 
a thromboembolism, and especially become entrapped within the vascular mesh within the 
Figure 1.1. A model of secondary haemostasis with both intrinsic, extrinsic, and common pathways.  Green arrows 
represent positive feedback mechanisms and red arrows represent negative feedback mechanisms (8)  
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lungs leading to a potentially fatal event called a Pulmonary Embolism (PE). The combination of 
DVT and thrombotic or pulmonary embolisms is collectively called Venous Thromboembolism 
(VTE). The development and presence of thrombotic disorders is the leading cause of death 
within the Western world, with 350000 patients affected every year in the United States alone 
(12). VTEs are highly common events with 201 VTE episodes occurring per 100,000 persons in 
2010/2011 across Europe, which marks a steady increase of VTE incidents from 1990 to 2011 
(13,14). 
1.2.2: Risk Factors of Thrombosis.  
Risk factors of thrombosis include trauma, surgery, cancer, age, pregnancy and use of oral 
contraceptives, lupus anticoagulants and immobilization during travel or lifestyle choices (15-
20). Whilst the risk factors are many, the cause of thrombosis is generally defined by Virchow’s 
triad which is the stasis of blood, endothelial cell injury, and altered blood coagulation (21).  
 
Figure 1.2.  A model of Virchow’s Triad displaying the three key events to trigger a thrombotic event. (22) 
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1.3 How To Detect And Measure Thrombosis 
1.3.1 Coagulation Assays  
As the risk of thrombosis is common and can be triggered by a variety of factors, there is a clinical 
imperative to monitor the coagulation cascade to evaluate the risks of haemostatic disruption. 
Laboratories have a set of assays to measure individual processes within the cascade. These 
assays include coagulation tests such as the prothrombin time (PT), activated partial 
thromboplastin time (APTT), thrombin clotting time (TCT), D-dimer levels and fibrinogen assays. 
Thrombophilia assays include, antithrombin levels (AT), dilute Russell’s viper venom test 
(DRVVT), protein C activity, free protein S activity, anti-Xa activity, prothrombin fragments 1+2 
(PF1+2), thrombin/anti-thrombin complexes (TAT) and the thrombin generation assay (TGA). 
The different assays and how their results are interpreted are detailed below.  
1.3.2 Coagulation Panel  
The coagulation panel contains a series of five routine assays that evaluates an 
individual’s ability to clot which include the PT, APTT, TCT, and quantitative assays 











Figure 1.3. Intrinsic and extrinsic pathways are the area of interest for the coagulation panel.  
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The prothrombin time measures the activities of the extrinsic and common pathways of 
coagulation based on the time required for a fibrin clot to develop. The assay measures the 
time taken for a sample of platelet poor plasma (PPP) to clot in the presence of phospholipids, 
tissue factor and calcium. The assay is dependent on the activity of FVIIa, FXa, FVa, 
prothrombin and fibrinogen (23). 
The activated partial thromboplastin time is used to measure the intrinsic and common 
coagulation pathways based on the amount of time required for a fibrin clot to develop. The 
APTT assay consists of the clotting time taken from citrated PPP and phospholipids on a 
negatively charged surface, after the addition of calcium chloride which initiates for fibrin clot 
formation.  
The thrombin clotting time evaluates the time taken for thrombin to form a clot in human 
citrated plasma, and detects the presence of thrombin inhibitors. The assay places a 
concentration of human thrombin into PPP and measures the time taken before a fibrin clot is 
formed. This reaction does not need calcium, unlike the APTT or PT, as the thrombin present in 
the sample can readily cleave fibrinogen and continue the reaction to the formation of a fibrin 
clot.  
The fibrinogen assay is used for the quantification of the protein fibrinogen in human plasma, 
usually using the Clauss method on an automated analyser. The Clauss fibrinogen assay uses 
diluted PPP (1:10 in buffer) together with phospholipids and high concentrations of thrombin 
(24). This is to ensure clotting times are independent of thrombin concentration over a wide 
range of fibrinogen levels found in samples. The reaction begins with the addition of thrombin 
to diluted plasma and the time taken for fibrinogen to produce a fibrin clot is recorded. The time 
is then compared to a calibration curve produced using a series of plasma dilutions produced 
from commercially available standard plasmas. The clotting time is inversely proportional to the 
plasma fibrinogen concentration.  
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The final assay within the coagulation panel is the D-dimer assay, which is used for the 
quantitative determination of cross linked fibrin degradation products, or D-dimers, in human 
plasma. Fibrinogen consists of three pairs of polypeptide chains that meet to form a central E 
domain and two D domains. When fibrinogen is activated by thrombin and becomes fibrin, the 
D-domains can bind to other fibrin E domains to form a fibrin clot. Adjacent D-domains are 
then covalently bound by FXIIIa. D-dimers are formed when cross-linked fibrin polymers 
covalently bound to each other are degraded by plasmin and broken down into the individual 
E and D domain fragments. These D-domain fragments or D-dimers can be measured as an 
indicator of coagulation activity via the use of an immunoturbidimetric assay containing 
polystyrene particles covered in monoclonal antibodies to bind D-dimers from the plasma onto 
the polystyrene surface. 
The coagulation panel can aid in diagnosing genetic or acquired factor deficiencies within the 
extrinsic and intrinsic pathways, liver failure, fibrinogen deficiency or disorders, disseminated 
intravascular coagulation (DIC), dysfibrinogenaemia and can also be used to rule out the risks 
of a thromboembolic event. The coagulation panel can monitor different therapies such as oral 
anticoagulants, fibrinolytic therapies, or the effects of heparin and direct thrombin inhibitors, 
such as dabigatran (25-28). 
1.3.3 Thrombophilia Panel 
The thrombophilia panel is used to determine an individual’s potential to clot and the risk of 
abnormal blood coagulation. The panel is comprised of four assays that measure the 
anticoagulant aspects of clotting. These assays include quantitative measurements of 











The Antithrombin III (ATIII) assay is used for the quantitative determination of the functional 
activity of ATIII in human plasma samples. ATIII is a natural anticoagulant which acts by inhibiting 
thrombin and FXa by forming an irreversible inactive complex. The ATIII assay uses plasma 
diluted in saline with heparin and excess thrombin to form a AT-Thrombin-Heparin complex. The 
residual thrombin then reacts and cleaves a chromogenic substrate to produce a colour change. 
The absorbance of the reaction is measured at 405nm and the rate of change in absorbance is 
inversely proportional to the activity of ATIII. With the use of a reference curve the rate of 
change in absorbance is used to determine the level of ATIII in the plasma (29).  
The DRVVT is used for the detection of lupus anticoagulants (LA) in human plasma using a two-
step screening and confirmation process containing Daboia russelii (Russell Viper) snake venom. 
Lupus anticoagulants are antibodies formed against negatively charged phospholipids or clotting 
Figure 1.4. Areas of interest for the thrombophilia panel. Thrombophilia panel assay targets are highlighted within 
oval and rectangle. 
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factors, including prothrombin, and are a significant risk factor in patients with unexplained 
thrombosis or women suffering recurrent foetal loss (30,31). The DRVVT screening test 
measures the amount of time taken for plasma to clot after the direct activation of FX. A 
prolonged clotting time could result from the presence of LA. The confirmatory test is nearly 
identical to the screening test but includes a high concentration of phospholipids to counteract 
the effects of LA. The screening test and the confirmatory test results are placed within a ratio 
(LA screen ratio/LA confirm ratio= Result ratio) to produce a normalised DRVVT ratio. If the 
plasma produces a normalised ratio more than 1.25 the sample is considered to have LA present, 
and if the ratio is less than 1.25 then the sample is confirmed to be LA negative. 
Factor deficiencies can also affect the DRVVT as a lack of factors can prolong the clotting times 
and can be mistaken for LA influences. To avoid mistakes, a prolonged sample can be mixed with 
normal plasma and undergo the DRVVT test again. The test is identical as the one before but the 
only difference is the addition of mixed pooled plasma to counteract the effects of factor 
deficiencies. The final ratio is calculated as previously described and LA is deemed to be present 
if the ratio over 1.25. If the ratios are below 1.25 for both tests with the mixed plasma, LA can 
be eliminated and factor deficiencies are suspected (32).  
The protein C assay uses a chromogenic substrate for the quantitative determination of active 
protein C in PPP. Protein C is a vitamin K-dependent coagulation inhibitor that degrades with 
FVa and FVIIIa, with protein S as its co-factor. The protein C assay uses snake (Akistrodon 
contortrix contortrix) venom to initiate protein C activation within sample plasma, with activated 
protein C cleaving a chromogenic substrate to produce a coloured substrate which is measured 
at 405nm. The level of absorbance from each sample is calculated using a standard curve 
produced from reference commercial plasma. The standard curve then provides a measurement 
of the amount of protein C present within the plasma.  
The free protein S assay used for the quantitative determination of free protein S in plasma by 
measuring the turbidity before and after inactivating FVa and FVIIIa in PPP (33). The assay uses 
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polystyrene particles coated in two different monoclonal antibodies to aggregate free protein S. 
The degree of aggregated particles is directly proportional to the level of free protein S in the 
plasma and is measured from the increase in turbidity over the course of the reaction. The assay 
is calibrated using commercial plasma standards, which provides a standard curve of known 
values and can be used to determine the level of protein S directly from the curve.  
The thrombophilia panel can be used for the determination of ATIII, free protein S, and protein 
C deficiencies which are linked to increased risk of VTE. The prevalence of ATIII deficiency in VTE 
patients is 1-2% which is higher compared to 0.02-0.2% of the normal population (34). Protein 
C deficiencies can also lead to thrombosis if genetically heterozygous and are non-compatible 
with life if homozygous (35). Free protein S deficiency, which is associated with an increased risk 
of VTE, can be caused by hepatic disorders, warfarin, viral infections, disseminated intravascular 
coagulation, oral contraceptives, and pregnancy (36). 
1.3.4 Anti-Xa Activity 
The anti-Xa activity assay is a measurement of the direct anti-Xa anticoagulants in human 
plasma. FXa cleaves prothrombin into thrombin and is the direct target for current anti-Xa direct 
acting oral anticoagulant drugs (DOACs), as inhibiting FXa inhibits thrombin generation and 
clotting. The chromogenic assay uses undiluted plasma with a chromogenic substrate and adds 
FXa into the mixture, triggering a competitive reaction between FXa hydrolysis of the substrate 
and FXa inhibition by a DOAC. The amount of coloured substrate produced is inversely 
proportional to the mass concentration of drug present in the plasma, which can be calculated 
using a calibration curve from known standards (37). Anti-Xa assays use a drug specific standard 
curve produced from the use of commercial standards as a method to determine the levels of 
drugs present in the plasma (38).  
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1.3.5 Coagulation Enzyme-Linked Immunosorbent Assays (ELISA)  
Enzyme-linked immunosorbent assays, or ELISAs, are used within a haematology laboratory to 
aid in quantifying individual molecules of interest. Two ELISA assays of interest would include 
the Prothrombin fragments 1+2 (PF1+2) and the Thrombin/antithrombin complex (TAT) assays. 
 
 
The prothrombin fragment 1+2 assay (PF1+2) can be used to quantify the amount of thrombin 
generated in a reaction in PPP. The conversion of prothrombin into thrombin releases a peptide 
called prothrombin fragment 1+2 which has been linked to thrombosis if found in elevated 
levels. The assay uses specific PF1+2 antibodies to attach to PF1+2 antigen on the surface of a 
micro titre plate. Additional peroxidase-conjugated antibodies are added and bind to free PF1+2 
before being rinsed, leaving only the bound PF1+2. The attachment of PF1+2 to its antibody in 
the presence of peroxide releases a coloured substrate, proportional to the PF1+2 concentration 
Figure 1.5. A model of haemostasis including activation, inhibition, inactivation and degradation markers. The 
prothrombin fragments 1+2 and thrombin/antithrombin complexes products are highlighted within the red oval 
(39). 
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present which is measured to provide the amount of PF1+2 present, and subsequently the 
amount of thrombin present in the sample which is useful to diagnosis the risk of thrombosis 
(40).  
The thrombin/anti-thrombin complex (TAT) assay is a quantitative ELISA kit specifically aimed at 
quantifying the presence of TAT within PPP.  After thrombin is activated and initiated fibrin 
clotting the process is inhibited by antithrombin to prevent unnecessary clot formation. 
Antithrombin binds to thrombin to form an inactive proteinase/inhibitor complex known as the 
thrombin/anti-thrombin complex, which is measured by this assay. The assay contains 
monoclonal antibodies for TAT and binds the complexes to a micro titre plate. The antibody 
bound TAT enzymes then reacts with an added chromogenic substrate to produce a measurable 
coloured substrate which is directly proportional to the concentration of TAT present (41). This 
assay is useful for the diagnosis of thrombotic events as higher TAT leads to a greater chance of 
developing a thrombus, or the incidence of DIC. The assay can also uncover if anti-thrombin or 
thrombin is low from excessive use or underproduction in patients with liver dysfunction, 
multiple trauma or septicaemia and is significantly more sensitive than other routine 
coagulation assays (42,43). 
1.3.6 Thrombin Generation Assay (TGA) 
The thrombin generation assay is a global assay used to monitor the complete formation and 
inhibition of thrombin within plasma with the use of a fluorogenic substrate. The global assay 
differs from a basic clotting time assay as the TGA measures the entire process of haemostasis 
and not just clot formation. The reaction is generated with the use of tissue factor and calcium 
to activate the coagulation cascade to cleave prothrombin into thrombin and generate a 
thrombin burst. The TGA is usually an automated procedure run by the Calibrated Automated 
Thrombogram (CAT) or the Ceveron Alpha® with TGA analyser. Both methods measure the 
entire space of thrombin activation which is represented by five parameters forming a TGA 
graph. These parameters include the lag time, the Endogenous Thrombin Potential (ETP), the 
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time-to-peak, the peak height, and the velocity index. The results received from different 
parameters are informative as the assay reveals the entire process of thrombin generation and 
inhibition within a plasma sample, not just the clotting time as other coagulation assays 
describe. Clotting times alone are insensitive to mild haemostatic disorders and increased 
coagulability, which is vital to diagnosing the increased risk of thrombosis 
 (44).  
The lag time is the measurement of time when tissue factor is added to a platelet poor plasma 
sample until there is a thrombin burst observed. The lag time is 4-6 minutes on average, or one 
sixth of the total reaction time and is defined as when more than 95% of the overall thrombin is 
still to be formed (46). Many other clotting time assays measure only this brief period and stop 
at the thrombin burst and do not provide a measurement of a patient’s overall coagulation 
potential, unlike the TGA. The area under the curve, or Endogenous Thrombin Potential (ETP), 
contains a measurement of the amount of thrombin generated overall within the reaction. With 
a patient’s ETP known, a clinician can accurately predict an individual’s coagulation potential 
which indicates if they are at risk of developing thrombosis, or to monitor the effects of anti-
Figure 1.6. A typical thrombin generation assay curve produced using the Calibrated Automated Thrombogram. 
Parameters measured include Lag time, Endogenous Thrombin Potential (ETP), Velocity index (VI), Time to peak and 
Peak height (Peak). Tail represents termination of the reaction. (45) 
VI 
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coagulant drugs on the patient (47). The peak height is the largest thrombin concentration 
detected during the reaction and time to peak is the minutes taken to reach that concentration. 
The final parameter is the velocity index which is the rate of the thrombin generated during the 
thrombin burst per minute which is useful to compare how intense the generation of thrombin 
is for the patient. 
1.4 Treatment of VTE and Review of DOACs and Coagulation Assays. 
The most common prophylactic treatment for thrombosis is the anticoagulant drug warfarin, 
approved by the FDA in 1954. It is a vitamin K antagonist (VKA) that inhibits coagulation by 
preventing the formation of vitamin K-dependent coagulation factors (48). Whilst warfarin is 
very effective for the treatment and prevention of thrombosis, there is a major disadvantage 
with the substance interacting with foods containing prominent levels of vitamin K as well as 
having constant fluctuations in drug levels which requires constant monitoring. These 
interactions decrease drug effectiveness and increase adverse interactions (49). New anti-
coagulant drugs have been developed to counter act the disadvantages of warfarin by acting 
directly on a specific clotting factor within the coagulation cascade instead of acting as a vitamin 
K antagonist.  
The new Direct Acting Oral Anticoagulant (DOAC) class is gaining greater representation for the 
treatment of thrombosis as global DOAC use has steadily increased within the last decade. 
DOACs, previously referred to as Novel Oral Anticoagulants (NOACs) are rapidly replacing 
traditional treatments due to their direct action, significantly less food/drug interactions, fixed 
dosage, and non-inferior efficacy (50). The current DOACs being prescribed include rivaroxaban, 
apixaban and edoxaban; direct FXa inhibitors and dabigatran; a direct thrombin inhibitor. With 
FXa or thrombin inhibited the conversion of fibrinogen into fibrin is blocked and clotting ability 
is significantly reduced. 
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DOACs are currently used to treat VTE and unlike VKA, do not requiring routine monitoring. 
However, there are occasions that monitoring DOACs would be advantageous such as during 
VTE events, serious bleeding, prior to urgent surgery or in suspected DOAC overdose (53). When 
monitoring drug concentrations, the two standard measurements taken include the peak and 
the trough levels. The peak level is the highest drug concentration available within the patient’s 
system after drug administration whilst the trough is the lowest concentration of the drug 
before the next dose. The difference between the two levels is the time taken since the last dose 
with peak usually around 2-4 hours and trough can be up to 24 hours since administration. The 
peak and trough measurements are important as they can identify a patient’s risk of overdosing, 
occurrence of drug toxicity, or if the drug concentration is still within therapeutic levels.     
 
 
The adaption of DOACs since 2010 has been rapid with medical guidelines undergoing change 
to preference DOACs as a frontline treatment option for VTE and atrial fibrillation (54). However, 
 Warfarin Rivaroxaban Apixaban Edoxaban Dabigatran 































20mg OD 2.5mg or 
5mg BD 









50% Renal 80% Renal 
OD- Once Daily, BD- Twice daily 
Table 1.1. Characterising the pharmacological properties of warfarin and the DOACs (50-52) 
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with the rapid adaption to DOACs there are still several questions within the literature on the 
effects of DOACs that have not been addressed. These include the effects of DOACs on routine 
and non-routine coagulation tests, such as false positives or prolonged clotting times within the 
DRVVT and APTT assays for LA testing (55). The effects of the concentration of the DOACs, at 
either peak or trough level is also very limited with some studies reporting DOAC effectiveness 
decreasing at trough concentrations (56). Also, it remains unknown whether the efficacy of 
DOACs are affected by obesity and if the practice of fixed dosage for DOACs is affected. 
1.5. DOAC Effects on Coagulation Assays.  
One of the largest advantages for DOAC therapies is that routine monitoring is non-essential, 
but this has led to unknowns regarding the effects of DOACs on routine and non-routine 
coagulation assays. There are circumstances where monitoring the effects of DOACs are 
important such as assessing which drug a patient is on and its concentration during emergency 
events such as bleeding, trauma, urgent surgery, and strokes (57), or accidental overdose. 
According to a study by Gosselin et al. (2016), less than 1% of laboratories that run routine 
coagulation tests perform additional quantitative FXa assays. This assumes that the routine 
tests such as PT and APTT can be used to accurately assess DOAC drug presence and plasma 
concentration (58). Gosselin et al. (2016) conducted a study which assessed the sensitivity of 
these methods to determine the DOACs anti-Xa effects on routine assays and some non-
routine coagulation assays. The study revealed that the PT and APTT are sensitive to 
interference from edoxaban and rivaroxaban but less for apixaban with longer clotting times 
experienced with increasing dosage of the drug. A study by Martinuzzo et al. (2013) ran silica 
clotting time assays as confirmation tests for rivaroxaban and dabigatran prolonged APTT 
samples but this test proved to be negative for any false positives (55). They concluded that 
the PT and APTT can be used as a screening test for the presence of anti-Xa DOACs but not to 
accurately provide their concentration.  
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The Gosselin et al. (2016) paper also studied a series of assays to evaluate if there are significant 
influences from the anti-Xa DOACs, which is recorded as changes in the baseline values by more 
than 15%. The study tested the Fibrinogen, ATIII activity, D-dimers, TCT, reptilase time, DRVVT, 
protein C, protein S, plasminogen, von Willebrand factor activity and antigen, as well as FVIII 
activity assays. The study concluded that there were no significant effects on these assays, with 
the exceptions of the ATIII, DRVVT, protein C and S, and Factor VIII assays. The ATIII, protein C 
and S assays produced falsely elevated results whilst the FVIII assay was also falsely decreased 
by the presence of DOACs, depending on the reagents and DOACs used (58).  
The DRVVT test for the presence of lupus anticoagulants produced increased normalised ratios 
which led to false positives for the presence of LA, a result that has been reported repeatedly 
for rivaroxaban, dabigatran and edoxaban (59-61), but interestingly very little for apixaban (62). 
A study conducted by Arachillage et al. (2015) investigated the influence of rivaroxaban on LA 
detection using in vitro and ex vitro samples by testing DRVVT at both peak and trough 
concentrations. The results demonstrate a concentration dependent increase of clotting time 
and increased rate of false positives for the DRVVT in 90% of their normal control and 92% in 
LA-negative in vivo samples when using peak (250ng/ml) rivaroxaban concentration with 
commercial assays (59) and led to ex vivo false positives for LA negative patients. However, false 
positives were not observed when the rivaroxaban plasma was at its trough (50ng/ml). It was 
concluded that peak, but not trough rivaroxaban concentrations will cause false positives in the 
DRVVT method (59). Acquiring only trough samples for testing is difficult however, as in most 
cases laboratories do not know if their samples are taken at peak or trough unless an anti-Xa 
assay is also performed, which has already been reported to be less than 1% of routine cases 
(54).  
Arachillage et al. (2015) also used Taipan venom time/Ecarin clotting time (TVT/ECT) assays for 
the detection of LA which reported no false positive results even at peak rivaroxaban 
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concentration (59). A previous study by Parmar et al. (2009) was similar in showing that TVT/ECT 
was more effective for determining the presence of LA in plasma containing VKAs compared to 
the DRVVT, but also stated that the assay is insensitive for individuals not receiving oral 
anticoagulants when compared to DRVVT (63). The results of the Parmar et al. (2009) study 
highlighted that the influence of VKA on DRVVT assays corresponds with the Arachillage et al. 
(2015) results for DOACs affecting the DRVVT assays. The reason TVT and ECT is unaffected by 
DOACs is due to the action of the venoms occurring independently from phospholipids and 
plasma concentrations of FV, FVII and especially FX. The DRVVT, however, is dependent on 
phospholipids for confirmation testing as the venom relies directly on the activation of FX which 
relies on the surface of phospholipids to continue the coagulation cascade, which means the 
assay is affected by DOACs. TVT/ECT was therefore stated to be reliably used for the detection 
of LA in patients undergoing DOAC therapy due to the absence of inference, whilst the 1st line 
LA detection method of DRVVT will produce false positives at peak concentrations.  
There are contradictions, however, regarding trough level assay validity and on the use of the 
TVT/ECT. Whilst all DOAC and LA studies have concluded that peak levels of DOACs led to false 
positives, there has been the recommendation that trough levels are safe to use, such as found 
in the Arachillage et al. (2015) and Gosselin et al. (2016) papers (58,59,61). A new study 
conducted by Ratzinger et al. (2016) focused solely on the effects of trough concentrations on 
LA assays and has reported false positives at even the lowest trough levels of all DOACs present 
for the DRVVT assay (56). At lower concentrations rivaroxaban and apixaban had a minor effect 
on APTT-LA confirmatory testing, whilst dabigatran caused major alterations with minimal 
dosage (56). Apixaban produced a false positive rate of 20% for the DRVVT which is unacceptably 
high, and is a contradiction to the earlier Hillarp et al. (2014) paper that stated apixaban does 
not cause false positive results (62). As there were discrepancies with the DRVVT, the TVT/ECT 
was recommended as an alternative LA assay by several papers (58,64,65) but the assay is 
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reportedly influenced by dabigatran at even trough levels (66). However, the current 2014 
guidelines for lupus anticoagulant detection support the TVT/ECT assays use for detecting LA 
when patients are undergoing anticoagulant therapies (67). The literature ultimately concludes 
that a DOAC neutralising agent for LA testing or the availability of a consensus based alternative 
testing system is highly desired and until these are a reality, LA testing for patients on DOAC 
should be avoided entirely.  
1.6 Effects of Obesity with DOACs on Coagulation Testing.  
There are unanswered questions involving DOACs and their effects on obese patients. It is well 
known that obesity is a risk factor for thrombosis, but only recently have the underlying pro-
thrombotic mechanisms been uncovered. Obesity is an epidemic with WHO estimating 1.9 
billion overweight and nearly 600 million obese adults globally, with an imbalance of energy 
intake and expenditure the main cause (68). Body Mass Index (BMI) estimates obesity and is 
classified as six weight groups which consist of underweight (<18.5), healthy (18.5-24.9), 
overweight (25.0-29.9), obesity I (30.0-34.9), obesity II (35-39.9) and obesity III (>40) as per 
National Health and Medical Research Council guidelines (69). Obesity is linked to the 
dysregulation of metabolic homeostasis which leads to systemic inflammation caused by 
inflammatory cytokines produced by adipocytes (70). The inflammation encourages activated 
macrophage recruitment which leads to further inflammation and systemic release of Tumour 
Necrosis Factor-α and interleukin 6 and 1β. These cytokines maintain the systemic inflammatory 
state which activates prothrombin signalling pathways leading to increased thrombin and tissue 
factor expression and ultimately the initiation of thrombosis (70). Normal anticoagulant 
mechanisms such as ATIII and protein C systems are also disrupted which further increase the 
risks of thrombosis (72). Platelets are also associated with obesity as mediators, with increased 
BMI leading to higher amounts of activated platelets which amplify the inflammation response 
via a range of mircoRNAs found within platelets (73).  
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Current dosing strategies for DOACs do not take BMI into consideration. However, there are 
studies that question the effectiveness of this practice. A major review of the published DOAC 
clinical trials revealed that most trials have not investigated obesity amongst their cohorts with 
no statistical comparisons, or have omitted the BMI and weight information from the results all 
together (74). The trials that have recorded the BMI have shown there is a relationship between 
the plasma drug concentration and body weight, but their conclusions have stated that there 
are no clinically relevant differences (74). A rivaroxaban clinical trial in 2007 examining the 
effects at extremities of weight stated there is no clinically related differences and that 
rivaroxaban is unlikely needed to be adjusted for weight (75). The RELY-ABLE long term clinical 
trial for dabigatran was a 2.8-year long trial to assess the additional safety of dabigatran but did 
not provide weight information (76). Three studies have published cases where obese patients 
experienced a VTE whilst on a regular regimen of dabigatran, because the dosage fell below 
therapeutic levels (77-79). Whilst the case reports suggested increased creatinine clearance as 
a possible cause, they also state that fixed dosage of dabigatran may be ineffective for obese 
patients. The dabigatran was replaced with warfarin or rivaroxaban which was stated to have 
stronger pharmacotherapeutic properties than dabigatran in obese patients but there are 
currently no recommendations for the replacement of DOACs (79). With the limitations of the 
data provided from most studies regarding obesity and the growing evidence of ineffective 
treatment with fixed dosage, further study of the effects of obesity on fixed DOACs dosage is 
required.  
1.7 Proposed Research  
With limitations of knowledge on the effects of DOACs on coagulation assays, the effectiveness 
of fixed dosage with peak and trough concentrations, and the effects obesity may play on DOACs 
and coagulation assays, we aim to expand our understanding of DOAC interference. With this 
study, we are aiming to characterise the effects of rivaroxaban and apixaban on coagulation 
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assays as there are limited studies, especially with apixaban. Apixaban’s relationship with 
coagulation testing has only been studied by the conflicting Hillarp et al. (2014) (62) and 
Ratzinger et al. (2016) (56) papers. This study will provide valuable information on how to 
interpret apixaban coagulation results. By comparing the peak and the trough concentrations it 
will be possible to characterise their effects as well as determine the amount of variation 
between peak and trough levels. This would lay the foundations for future guidelines within 
emergency medicine regarding DOAC monitoring and would either support or discredit the use 
of the DRVVT assay as the 1st line test for LA whilst on peak or trough rivaroxaban and apixaban 
levels. Peak and trough samples are also useful for assessing obesity as a factor as studies have 
indicated that trough levels from fixed dosed obese patients may be ineffective for not only 
dabigatran but also apixaban and rivaroxaban (78,79). Characterising if there are additional 
statistical differences between weight with coagulation assay results would also be sought after 
as this area does not have any current published data. If additional undocumented effects 
between obese and non-obese patients are discovered, this study can be used to help prevent 
medical emergencies by improving management and monitoring of this high-risk group.  
1.8 Statement of Aims 
The DOAC influence on coagulation and thrombin generation assays still requires further 
research as there are contradictions in the literature, especially their impact on peak and 
trough levels. Whilst current guidelines and studies have reported similar discrepancies with 
DOACs affecting assays, there is a lack of consensus on how much they are affected and their 
final interpretations. There is also a lack of statistical information on the significance of obesity 
with patients taking DOACs, as many studies are now questioning the current 
recommendation of fixed dosage.  
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It is vital to have rigorous, accurate and reproducible methods to monitor DOACs efficacy and 
therapeutic effects, especially considering the current limitations of knowledge within this 
field. This study will be important to provide clinicians future recommendations on fixed 
dosages for obese patients experiencing thromboembolic disorders. Therefore, the further 
understanding of how these drugs relate to coagulation assays will allow for the improved 
management and monitoring of patients, especially obese, prescribed DOACs. With improved 
management, it can be expected to lead to a reduction of adverse effects associated with this 
class of pharmacotherapeutic intervention. 
 
To gain further understanding within this field we hypothesise that the DOACs rivaroxaban 
and apixaban exert a dose dependent effect on coagulation parameters and thrombin 
generation.  
To prove this hypothesis this study aims to; 
1. Characterise and compare the effects of rivaroxaban and apixaban on routine and 
non-routine coagulation parameters. 
2. Determine whether samples taken at trough levels have less interference on 
coagulation assays than at peak levels. 
3. Determine the effects obesity has on coagulation parameters and its interferences 








2.1 Reagents and Suppliers 
2.1.1 Blood Collection 
Equipment      Catalogue No., Suppliers 
Plastic citrate tube, .109 M/3.2%   363095; Becton Dickinson PTY Ltd. 
Plastic whole blood tube with spray-coated     
K2EDTA       367839; Becton Dickinson PTY Ltd. 
BD SST tube with silica clot activator, polymer  
gel, silicone-coated interior    367954; Becton Dickinson PTY Ltd. 
21-G x .75-in needle with 12-in tubing and  
luer adapter      367365; Becton Dickinson PTY Ltd. 
Norma icon 3 Haematology Analyzer   Norma Diagnostika GmbH 
2.1.2 Thrombin Generation Assay 
Reagents      Catalogue No., Suppliers 
TGA LowRC (Rc low conc. of phospholipid micelles  5006224; Technoclone TGA GmbH 
containing rhTF in Tris-Hepes-NaCl Buffer )    
TGA Sub (1mmoL Z-Gly-Arg-AMC)   5006237; Technoclone®  TGA GmbH 
TGA Reaction Buff (Tris-Hepes-NaCl Buffer)  5006370; Technoclone®  TGA GmbH 
TGA Control High (Human Plasma with increased 5006322; Technoclone®  TGA GmbH 
thrombin generation, lyophilized) 
TGA Control Low (Human Plasma with decreased 5006332; Technoclone®  TGA GmbH 
thrombin generation, lyophilised) 
25mL CaCl2 (25mmol/L)    5277017; Technoclone®  TGA GmbH  
Equipment 
Micro tube 1.5mL PP     72.692.005; Sarstedt,  
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ART ™ Pre-sterilized barrier pipette tips (10,20,200, 2140-05-HR, 2149-P05-HR, 2270,  
1000 uL)      2179-05-HR; Thermo Scientific  
Ceveron Alpha® with TGA analyser   9820010; Technoclone®  TGA GmbH 
2.1.3 TAT and PF1+2 ELISA 
Reagents       Catalogue No., Suppliers 
Enzygnost® TAT micro ELISA Kit    OWMGG15E0503 (971); ©Siemens AG 
Enzygnost® F 1+2 micro ELISA Kit   OPBDG03E0503 (1445); ©Siemens AG 
Equipment 
ART ™ Pre-sterilized barrier pipette tips (10,20,  2140-05-HR, 2149-P05-HR, 2270, 
200,1000 uL)       2179-05-HR; Thermo Scientific  
Thermo shaker PHMP (V.5GW)    Grant-Bio, Keison Products 
Multipette® (X)stream      4986000831; Eppendorf   
Eppendorf Combitips advanced® (1mL, 10mL)  0030089430, 0030089464;  Eppendorf 
Ovation Pipette E8 25-1250 µL    1160-1250; VISTALAB TECHNOLOGIES,  
I         INC. 
VistaRak™ 1250 µL pipette tips    4060-3004; VISTALAB TECHNOLOGIES, 
I       INC. 
FLUOstar Omega microplate reader   0415F0005B; BMG LABTECH GmbH 
FLUOstar Omega MARS Data Analysis Software   
(V3.10R6)       BMG LABTECH GmbH 
2.1.4 Sysmex CS-5100 Assays 
Reagents      Catalogue No., Suppliers 
Thromborel® S Reagent     OUHP47; ©Siemens AG 
Dade® Actin® FSL Activated PTT Reagent  B4219-2; ©Siemens AG 
Thromboclotin® Reagent    2810; ©Siemens AG 
Dade® Thrombin Reagent    B4233; ©Siemens AG 
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Innovance® D-Dimer     OPBP11; ©Siemens AG 
LA1 screening reagent/ LA2 Confirmation Reagent OQGP172, OQGR132; ©Siemens AG  
Innovance® Free PS Ag     OPGLGO3CO101(201); ©Siemens  
Berichrom® Protein C     NC1119001; ©Siemens AG 
Berichrom® Antithrombin III (A)    OWWRG17E0503; ©Siemens AG 
STA®- Rivaroxaban Calibrator    00704; DIAGNOSTICA STAGO  
STA®- Rivaroxaban Control    00706; DIAGNOSTICA STAGO 
STA®- Apixaban Calibrator    01075; DIAGNOSTICA STAGO  
STA®- Apixaban Control     01074; DIAGNOSTICA STAGO 
Equipment 
ART ™ Pre-sterilized barrier pipette tips (10,20,  2140-05-HR, 2149-P05-HR, 2270, 
200,1000 uL)       2179-05-HR; Thermo Scientific  
Sysmex® CS-5100 System    Sysmex® Corporation 
2.2 Location of Suppliers 
BMG LABTECH GmbH, Ortenberg, Germany 
Becton Dickinson PTY Ltd., Franklin Lakes, USA 
DIAGNOSTICA STAGO, Paris, France 
Eppendorf, Hamburg, Germany 
Keison Products, Chelmsford, England 
Norma Diagnostika GmbH, Untertullnerbach, Austria 
SARSTEDT AG & Co, Nümbrecht, Germany 
©Siemens AG, Munich, Germany  
Sysmex® Corporation, Kobe, Japan 
Technoclone GmbH, Vienna, Austria 
Thermo Scientific, Waltham, USA 
VISTALAB TECHNOLOGIES INC, Brewster, USA 





This project was approved by the Hollywood Private Hospital Research Ethics Committee on 
the 2nd of May 2017 (Reference Number: HPH408), and received reciprocal approval by the 
Murdoch University Human Ethics Committee (Reference Number: 2017/115) on the 2nd of 
June 2017.  
3.2 Description of the Research Design: 
This study was conducted with the recruitment of 40 VTE patients and 1 AF patient currently 
undergoing anticoagulant therapy with either rivaroxaban (20mg), or apixaban (2.5mg or 5mg) 
oral tablets at their routine haematologist appointments. Twenty healthy volunteers were also 
recruited to serve as a control group. The relevant medical history of all the patients were 
checked for internal influences such as factor/protein deficiencies. The medical histories of the 
patients included 9 cases of Factor V Leiden, 6 cases of increased Factor VIII, 2 with anti-
B2GP1, 2 with Anticardiolipin antibodies present, 1 Prothrombin gene mutation, and a protein 
S deficiency.  
The Inclusion Criteria includes;  
• Identified individuals already being treated with anticoagulant therapy with 
rivaroxaban or apixaban for prevention or treatment of venous thromboembolism 
associated with non-valvular atrial fibrillation or previous venous thromboembolism. 
•  A small group (n=20) of healthy age and gender matched volunteers will also be 
included in this study.  
Exclusion Criteria includes;  
• Patients who are unable or unwilling to provide informed consent. 
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• Patients on any other anticoagulant treatment (e.g. heparin, warfarin), or are currently 
taking aspirin and/or fish oils.  
The participants provided written informed consent to the study for the collection of 
clinical and laboratory information, and to provide 16.2mL of blood (six 2.7ml citrate 
tubes) once if in the control cohort, or at trough and three hours later at peak for DOAC 
patients. A screening log was kept and the reasons documented for any non-participation 
from eligible subjects. The participant’s height and weight was measured and recorded 
and the BMI was calculated (Weight (kgs)/Height (cms)/Height (cms) *10000). Between 
the 2nd of June 2017 to the 25th of August 2017 61 participants were recruited consisting of 
33 females and 28 males, with a median age and weight of 55 years and 75.8kg, and 57.5 
years and 90.4kgs respectively. The median BMIs of males and females was 28.4 and 27.9 
respectively. Participants were sorted into rivaroxaban, apixaban or control cohorts. 
Patients undergoing apixaban treatment were prescribed with 2.5mg or 5mg oral tablets, 
so the apixaban cohort further split into 2.5 or 5mg sub-cohorts to represent the 
differences between the two doses. The rivaroxaban and apixaban cohorts were required 
to provide a blood sample immediately before their daily dosage time for the drug trough 
concentration, and then three hours later for the peak. The control cohort provided only 
the one sample. The ethnic background of the participants consisted of 93.6% Caucasian, 
1.6% African and 4.8% Indian. The cohorts were also organised into weight sub-groups 
(Table 3.1).  
 
 





Blood was collected into evacuated siliconized glass Vacutainer tubes (BD Vacutainer System, 
Plymouth, United Kingdom) containing 3.2% sodium citrate in a ratio of 1:9 with blood and 
centrifuged at 822 x g for 12 minutes, followed by repeat centrifugation of the separated 











Rivaroxaban 7 3 5 2 3 
Apixaban 5 7 6 1 2 
Controls 6 10 3 1 0 
Total: 18 20 14 4 5 
Total: 61 
Figure 3.1. A flowchart displaying the division of the sample population into individual cohorts and sub-cohorts. 
Table 3.1: The number of participants in each BMI category, per cohort. 
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(Eppendorf, Hamburg, Germany) and samples were frozen at -80°C until testing. Blood 
processing was completed within 30 minutes of collection. 
 
 
3.3 Testing Methods. 
3.3.1. Coagulation and Thrombophilia Panels.  
The Prothrombin time (Thromborel® S), Activated Partial Thromboplastin Time (Dade® Actin® 
FSL Activated PTT Reagent), Thrombin clotting time (Thromboclotin®), Fibrinogen (Dade® 
Thrombin Reagent), D-Dimer (Innovance® D-Dimer), DRVVT (LA1 screening reagent/ LA2 
Confirmation Reagent), Protein S (Innovance® Free PS Ag), Protein C (Berichrom® Protein C) 
and Antithrombin III (Berichrom® Antithrombin III (A)) assays and Liquid Anti-Xa (Stago, Paris, 
France) were prepared before loading within the Sysmex ® CS-5100 analyser (Sysmex® 
Figure 3.2. A flowchart of the sample collection and preparation procedure.  
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Corporation, Kobe Japan) after samples were thawed in a 37°C water bath. Samples were 
loaded ten at a time into the Sysmex® CS-5100 analyser and automatically processed as 
described by Flieder et al. (2016) (80).  
3.3.2. Thrombin Generation Assay:  
The Thrombin Generation assay was performed using the Ceveron Alpha® with TGA analyser 
(Technoclone Gmbh, Vienna, Austria) using TGA TechnoThrombin reagents (Technoclone 
GmbH, Vienna, Austria). TGA reagents were first prepared with the addition of 1mL ultrapure 
water to TGA LowRC, TGA Reaction Buffer, TGA Control High, TGA Control Low, and 3mL to the 
TGA Substrate and left for 10 minutes at 15-25°C. The reagents were scanned into the Ceveron 
analyser before up to 36 plasma samples were thawed in a 37° water bath and loaded into the 
analyser. The Ceveron Alpha measures the complete thrombin formation and inhibition within 
plasma via the cleavage of a fluorogenic substrate by thrombin.  The analyser records and 
measures the thrombin generation kinetics continuously to produce a thrombogram which is 
represented by the five parameters.   
3.3.3. ELISA Assays 
The Enzygnost thrombin/antithrombin complex micro, and Enzygnost prothrombin fragments 
1+2 micro ELISA kits contain 96 well plates and employ reagents provided by Siemens 
(Siemens, Newark Germany). The Enzygnost prothrombin fragments 1+2 micro ELISA protocol 
included the preparation of reagents including the formation of; washing solution POD, Anti-
Human Prothrombin/POD Conjugate Reagent, Chromogen working solution (protected from 
sunlight), Human prothrombin fragment F 1+2 standards containing 20,80,400 and 1200 
pmol/L, and lyophilised human plasma as a positive control. Testing began by adding 50 μL of 
Tris buffer solution (100mM) followed by PF1+2 Standard / Sample to each well in duplicate, 
before agitation and incubation at 30 minutes at 37°C.  All wells were aspirated and filled with 
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wash Buffer (300μl/well) and aspirated again. Process was repeated once and 100 μL/well of 
conjugate solution was added before being covered with fresh adhesive foil and incubated for 
15 minutes at 37°C. Sample wells were washed 3 times with Wash Buffer (300 μL/well) before 
Chromogen Buffer/Substrate (100 μL/well) was added. Wells were covered with fresh adhesive 
foil, and incubated for 15 minutes at 15-25°C, protected from light. 100 μL/well of Stop 
Solution (0.25 M sulphuric acid) was added and the plate was read at 450 nm absorbance 
within one hour using the FLUOstar Omega plate reader (BMG Labtech, Ortenberg, Germany) 
and results were calculated using Omega Mars analysing software (BMG Labtech, Ortenberg, 
Germany). 
 The Enzygnost Thrombin/Anti thrombin complex ELISA protocol included the preparation of; 
washing solution POD, Anti-AT III/POD Conjugate Reagent, thrombin/anti-thrombin complex 
standards containing 2,6,20 and 60 μg/L, and lyophilised human plasma as a positive control. 
50 μL of Tris buffer solution (100 mM) followed by 50 μL TAT standard/ plasma sample was 
added to each well in duplicate before agitation, covered with adhesive foil and incubated for 
15 minutes at 37°C.  All wells were aspirated and filled with Wash Buffer (300 μl/well) and 
aspirated. Washing process was repeated twice and conjugate solution (100 μL/well) was 
added before being covered with fresh adhesive foil and incubated for 15 minutes at 37°C. 
Working chromogen solution was then prepared during this incubation step by transferring 10 
mL of buffer/substrate POD (hydrogen peroxide (0.3 g/L)) in a citrate buffer solution into a vial 
of chromogen POD (o-phenylenediamine dihydrochloride), and was shaken to dissolve. The 
plate was washed 3 times with wash buffer (300 μL/well) and freshly made chromogen 
Buffer/Substrate (100 μL/well) was added. Plate was then covered with fresh adhesive foil and 
incubated for 15 minutes at 15-25°C, protected from light. 100 μL/well of stop solution (0.5 N 
sulphuric acid) was added and the plate was read at 492 nm absorbance within one hour using 
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the FLUOstar Omega plate reader (BMG Labtech, Ortenberg, Germany) and results were 
calculated using Omega Mars analysing software (BMG Labtech, Ortenberg, Germany). 
3.4 Statistical Analysis: 
The results of the assays were analysed using three different methods. The results were first 
analysed as a comparison of the peak DOAC cohort and the controls to determine if 
rivaroxaban or apixaban influence the various assays. This was statistically performed using a 
2-sample unpaired t-test assuming equal variances using Microsoft excel analysis ToolPak 
software (Microsoft ver.1707).  Apixaban and rivaroxaban cohorts peak and trough drug 
concentrations were then analysed using a paired two sample for means t-test. As the 
apixaban cohort consists of patients taking 2.5mg tablets or 5mg tablets, the cohort was split 
into sub-cohorts of peak and trough 2.5mg and 5mg for analysis purposes. The 2.5mg and 5mg 
apixaban sub-cohorts at both peak and trough were compared to the normal cohort using the 
2-sample t-test assuming equal variance and a paired t-test when comparing peak and trough 
2.5mg or 5mg apixaban results.  
The peak rivaroxaban, apixaban, and control cohorts were also evaluated to establish whether 
there is a relationship between the results and the patient’s weight, via the use of the Kruskal 
Wallis test, also known as the single factor ANOVA method. The significance level for all 
statistical testing is α < 0.05.   
4. Results: 
4.1 Effects of Peak and Trough Rivaroxaban and Apixaban Concentrations on 
Coagulation Parameters 
The rivaroxaban cohort consisted of 20 patients prescribed a daily dosage of 20mg oral tablets 
for the treatment and/or prevention of VTE. The average concentration of rivaroxaban at peak 
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dose was 233.06ng/ml. The Apixaban cohort consisted of 21 patients currently prescribed 
either 2.5mg or 5mg oral tablets with the average concentration of 86.77ng/ml with peak 
2.5mg apixaban, and 165.31 ng/ml with peak 5mg apixaban for the treatment and/or 
prevention of VTE, or atrial fibrillation.  
4.1.1 Prothrombin Time  
The Prothrombin time assay result was influenced by rivaroxaban as there was prolongations 
in clotting time between the rivaroxaban and control cohort (p<0.0001). The mean and range 
of the prothrombin time was also prolonged. When rivaroxaban trough and peak cohorts were 
analysed using a paired t-test the peak concentrations had significantly more impact on the 
assay than at trough (p<0.0001 Table 4.1). Comparison of the trough to the normal cohort was 
found to not have significant differences (p=0.73 Table 4.1). 
The peak apixaban cohorts were not found to have a difference in prothrombin time (2.5mg: 
p=0.16, 5mg: p=0.87 Table 4.1). However, there were differences between peak and trough 
concentrations for both doses, as the peak prothrombin time was prolonged compared to the 
trough (2.5mg: p<0.001, 5mg: p<0.01 Table 4.1), but was still contained within the range of the 
controls.  





















12.71 15.54 * 12.59 12.85 * 12.41 13.42 * 12.64 
Range 9.79-
15.62 









- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-
test  
- 4.50973E-08 0.73868 0.78469 0.54677 0.16765 0.87851 
Paired t-test  - - 2.59134E-11 - 0.00092 - 0.00337 
Table 4.1. The mean Prothrombin time, range and drug concentration for each cohort. p values for unpaired and paired t-
tests are provided. Bold figures represent significance. * represents comparison of cohort to control 
 






























































































4.2.2 Activated Partial Thromboplastin Time  
The Activated Partial Thromboplastin time assay was found to be influenced by 
rivaroxaban at peak concentrations (p<0.001 Table 4.2). Comparison of the effects of 
peak and trough rivaroxaban levels described prolonged clotting times, with greater 
assay interference at peak levels than at trough (p<0.0001 Table 4.2). The 2.5mg and 
5mg Apixaban cohorts did not considerably influence the APTT assay at peak 
concentrations or at trough time (Table 4.2). The comparison of influence between 
*** 
*** 
Figure 4.1. The Prothrombin time for each cohort. Error bars represent mean with standard error of the mean. ** represents 
statistical significance p<0.01, *** represents statistical significance p<0.001 
 





peak and trough concentrations were not significantly different for the 2.5mg tablets, 



















































- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-test  - 0.00037 0.34368 0.183228 0.127573 0.507745 0.099797 
Paired t-test  - - 1.50E-09 - 0.35989 - 0.00016434 











































































Figures 4.2. The Activated Partial Thromboplastin time for each cohort. Error bars represent mean with standard error of the 
mean. ** represents statistical significance p<0.01, *** represents statistical significance p<0.001.  
 
Table 4.2. The mean Activated Partial Thromboplastin time, range and drug concentration for each cohort. p values for unpaired 
and paired t-tests are provided. Bold figures represent significance. * represents comparison of cohort to control. 
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4.1.3 Thrombin Clotting Time  
The thrombin clotting assay was not affected by the peak presence of rivaroxaban or 
apixaban. The trough concentrations also did not affect the assay in a significant way. 
When peak and trough were compared there was no major changes between 
rivaroxaban and both apixaban cohorts (Table 4.3). 














































- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-test  - 0.56243 0.53017 0.4248 0.20601 0.7229 0.807 
Paired t-test  - - 0.58478 - 0.41288 - 0.82025 
Table 4.3. The mean Thrombin clotting time, range and drug concentration for each cohort. p values for unpaired and 
paired t-tests are provided. * represents comparison of cohort to control 
 





































































































4.1.4 Fibrinogen  
The fibrinogen assay was not affected by the peak presence of rivaroxaban or by the 
apixaban cohorts. The trough concentrations also did not affect the assay in a 
significant way (Table 4.4). When peak and trough were compared there was no 
significant differences between rivaroxaban (p=0.64 Table 4.4), and the 5mg apixaban 
cohorts (p=0.83 Table 4.4), but there were statistically significant differences between 
the 2.5mg cohort (p<0.05 Table 4.4).  
 
 
Figure 4.3. The Thrombin clotting time for each cohort. Error bars represent mean with standard error of the mean.  
 












































3.269 3.402 4.08 4.16 




- 234.94 27.095 86.77 31.924 165.31 65.92 
 Unpaired t-test  - 0.28152 0.29698 0.32415 0.39444 0.87304 0.93821 
Paired t-test 
(0.05) 















































































Table 4.4. The mean fibrinogen level, range and drug concentration for each cohort. p values for unpaired and paired t-
tests are provided. Bold figures represent significance. 
 
Figures 4.4. The fibrinogen level for each cohort. Error bars represent mean with standard error of the mean. * 
represents statistical significance p<0.05 
 




The D-Dimer assay was not affected by the peak or trough presence of rivaroxaban or 
apixaban. There were also no differences between the peak and the trough 











































































































0.254* 0.262 0.558* 0.582 




- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-
test  
- 0.70839 0.44982 0.4844 0.40009 0.067 0.0759 
Paired t-test - - 0.20271 - 0.39936 - 0.43955 
Table 4.5. The mean D-dimer level, range and drug concentration for each cohort. p values for unpaired and paired t-tests 
are provided. * represents comparison of cohort to control 
 
 
Figures 4.5. The D-Dimer level for each cohort. Error bars represent mean with standard error of the mean.  
 




4.1.6 Dilute Russell Viper Venom Test 
The DRVVT normalised ratio (LA screen ratio/LA confirm ratio) is significantly 
influenced by rivaroxaban at both peak (p<0.0001 Table 4.6) and at trough (p<0.001 
Table 4.6) concentrations. The ratio increases when increasing amounts of rivaroxaban 
are present, with a maximum concentration of 446.04 ng/ml producing a ratio of 2.34. 
The difference between peak and trough rivaroxaban concentrations was also 
significant (p<0.0001 Table 4.6). The DRVVT normalised ratio was also influenced by 
both peak apixaban cohorts but to less than half the extent of rivaroxaban (2.5mg: 
p<0.05, 5mg: p<0.01 Table 4.6). The trough concentration of the 2.5mg apixaban was 
not found to be different than the controls (p=0.08 Table 4.6), but the 5mg trough 
concentration was (p<0.01 Table 4.6). It was also found that there were no notable 
differences between the peak and trough influences of apixaban for both 2.5 and 5mg 
doses (2.5mg: p=0.26, 5mg: p=0.36 Table 4.6).  
If the DRVVT normalised ratio is over 1.25, it is recorded as positive for the presence of 
LA. The participants had not previously recorded the presence of LA before partaking 
in the study, so ratios over 1.25 are considered false positives. The results of the 
rivaroxaban cohort included false positives for the majority of the trough and all the 
peak samples. Apixaban was not as influential as rivaroxaban and included five false 
positive at peak apixaban concentration and four false positives within the trough 
concentration between both doses.   




























1.04069 1.775 * 1.338 1.152 * 1.119 1.214 * 1.175 
Range 0.83-
1.25 





- 234.94 27.095 86.77 31.924 165.31 65.92 
 Unpaired t-
test  
- 3.3442E-14 1.1595E-04 0.0338 0.0846 0.0016 0.0038 
Paired t-test - - 2.0889E-08 - 0.2623 - 0.3665 
*** 
Table 4.6. The mean DRVVT normalised ratio, range and drug concentration for each cohort. p values for unpaired and 
paired t-tests are provided. Bold represents significance. * represents comparison of cohort to control 
 
 



















































Matthew Halliday  DO ACT Study 2017 
pg. 42 
 






































































4.1.7 Protein S 
The Free Protein S assay was not found to be notably influenced by the peak presence of 
rivaroxaban or 2.5 or 5mg apixaban dosage when compared to the controls. The troughs also 




Figures 4.6. The DRVVT normalised ratio for each cohort. Error bars represent mean with standard error of the mean.  
* represents statistical significance p<0.05, ** represents statistical significance p<0.01, *** represents statistical 
significance p<0.001 
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peak and trough concentrations for both DOACs also did not differ in their influence on the 






































































































Mean % Free 
Protein S 
present 
















- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-
test  
- 0.19434 0.10678 0.32855 0.76257 0.18074 0.2556 
Paired t-test - - 0.25781 - 0.44311 - 0.78034 
Figure 4.7. The Percentage level of Free Protein S for each cohort. Error bars represent mean with standard error of the 
mean. Highlighted area is discussed further (5.1.2). 
 
Table 4.7. The mean level of free protein S, range and drug concentration for each cohort. p values for unpaired and paired 
t-tests are provided. * represents comparison of cohort to control 
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4.1.8 Protein C  
The Protein C assay was found to not be notably influenced by the peak presence of 
rivaroxaban or 2.5 or 5mg apixaban dosage when compared to the controls. The 
troughs also were not remarkably different to the controls for rivaroxaban or both 
apixaban doses. The peak and trough concentrations for both DOACs also did not differ 
in their influence on the assay (Table 4.8).  





















121.02 125 * 125.55 131.5 * 
 













- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-test  - 0.59854 0.55426 0.3805 0.22639 0.07092 0.06682 
Paired t-test - - 0.70072 - 0.06123 - 0.93479 
Table 4.8. The mean level of protein C, range and drug concentration for each cohort. p values for unpaired and paired t-
tests are provided. * represents comparison of cohort to control 
 














































































 4.1.9 Antithrombin III 
The antithrombin III assay was not notably influenced by the presence of peak 
rivaroxaban or apixaban cohorts. Trough concentrations of both apixaban doses and 
rivaroxaban also did not influence the assay. There were also no statistically significant 
differences between the peak and trough concentrations for both DOACs (Table 4.9). 






































- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-
test  
- 0.23385 0.13767 0.60949 0.89117 0.39460 0.20931 
Paired t-test - 0.58579 0.58579 0.15805 0.15805 0.6348 0.6348 
Figure 4.8. The Percentage level of protein C for each cohort. Error bars represent mean with standard error of the mean 
 
Table 4.9. The mean percentage of ATIII, range and drug concentration for each cohort. p values for unpaired and paired 
t-tests are provided. * represents comparison of cohort to control 
 


















































































4.1.10 Thrombin/Antithrombin complex 
 The Thrombin/Antithrombin (TAT) complex assay was found to not be notably 
influenced by the peak presence of rivaroxaban or 2.5 or 5mg apixaban dosage when 
compared to the controls. The troughs also were not remarkably different to the 
controls for rivaroxaban or both apixaban doses. The peak and trough concentrations 
for both DOACs also did not differ in their influence on the assay (Table 4.10). 
 
Figure 4.9. The Percentage level of Antithrombin III for each cohort. Error bars represent mean with standard error of the mean. 
 
Table 4.10. The mean percentage of TAT, range and drug concentration for each cohort. p values for unpaired and paired 
t-tests are provided. * represents comparison of cohort to control 
 






















































































































3.5 2.62* 2.45 3.18* 2.69 2.19* 4.32 




- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-
test  
- 0.37991 0.20907 0.7853 0.3351 0.22761 0.64159 
Paired t-test - 0.77454 0.77454 0.4082 0.4082 0.2909 0.2909 
Figure 4.10. The quantity of Thrombin-Antithrombin complexes for each cohort. Error bars represent mean with standard 
error of the mean 
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4.1.11 Prothrombin Fragment 1+2  
The prothrombin fragment 1+2 (PF1+2) assay was found to not be notably influenced 
by the peak presence of rivaroxaban or 2.5 or 5mg apixaban dosage when compared 
to the controls. The troughs also were not remarkably different to the controls for 
rivaroxaban or both apixaban doses. The peak and trough concentrations for both 
DOACs also did not differ in their influence on the assay (Table 4.11).  



























164.2* 185.53 173.07* 191.8 
Range 27.67-
307.33 







- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-test  - 0.23983 0.12788 0.892 0.43137 0.56751 0.16405 
Paired t-test - 0.39793 0.39793 0.33149 0.33149 0.19351 0.19351 
Table 4.11. The mean percentage of PF1+2, range and drug concentration for each cohort. p values for unpaired and 
paired t-tests are provided. * represents comparison of cohort to control 
 

























































































4.1.12 Thrombin Generation Assay 
The thrombin generation assay is recorded as five interlinked parameters which 
provide a model of a patient’s overall haemostatic potential.  
Lag Time:  
The Lag time was found to be prolonged with the presence of peak concentrations 
rivaroxaban when compared to the healthy controls (p<0.001 Table 4.12). The 
apixaban cohorts did not produce a difference between the peak concentrations 
results and the healthy controls (2.5mg: p=0.49, 5mg: p=0.58 Table 4.12). The trough 
concentrations of both rivaroxaban or apixaban did not affect the assay significantly 
(Table 4.12). There was a marked increase in lag time for the peak concentrations 
Figure 4.11. The quantity of Prothrombin Fragments 1+2 for each cohort. Error bars represent mean with standard error 
of the mean 
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compared to the trough concentration for rivaroxaban (p<0.01 Table 4.12), but this 





































































































4.46 5.55* 4.96 4.69* 4.35 4.6* 4.83 
Range 3.22-
5.7 




- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-
test 
- 0.00055 0.10437 0.49786 0.64073 0.58183 0.25549 
Paired t-test - - 0.00290 - 0.1458 - 0.3417 
Table 4.12. The mean lag time, range and drug concentration of the TGA for each cohort. P values for unpaired and paired t-




Figures 4.12. The TGA lag Time for each cohort. Error bars represent mean with standard error of the mean. ** 
represents statistical significance p<0.01, *** represents statistical significance p<0.001 
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Time to Peak: 
The Time to peak (tPeak) was found to be prolonged with the presence of peak 
rivaroxaban concentrations when compared to the healthy controls (p<0.0001 Table 
4.13). The 5mg apixaban cohort was not found to be prolonged (p=0.93 Table 4.13), 
but the peak 2.5mg concentration result has a notable prolongation when compared 
to the healthy controls (p<0.05 Table 4.13). The trough concentrations of rivaroxaban 
also displayed a prolongation for tPeak (p<0.01 Table 4.13). The trough apixaban doses 
did not affect the assay significantly (2.5mg: p=0.16, 5mg: p=0.5 Table 4.13). There was 
a marked increase for the time to peak for the peak concentrations compared to the 
trough concentration for rivaroxaban (p<0.0001 Table 4.13), but this was not seen for 
both apixaban doses (2.5mg: p=0.07, 5mg: p=0.53 Table 4.13).  


















Mean Time to 
Peak (minutes) 
10.98 19.23* 15.93 15.31* 12.93 10.9* 11.88 






- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-test  - 1.6E-07 0.00385 0.02624 0.16264 0.93692 0.50216 
Paired t-test - - 8.838E-07 - 0.0765 - 0.53791 
Table 4.13. The mean Time to peak, range and drug concentration of the TGA for each cohort. p values for unpaired and 
paired t-tests are provided. Bold represents significance. * represents comparison of cohort to control 
 





























































































The Peak Height (PH) was found to be depressed with the presence of peak 
rivaroxaban concentrations when compared to the healthy controls (p<0.0001 Table 
4.14). The 5mg apixaban cohort was not found to be different (p=0.12 Table 4.14), but 
the peak 2.5mg concentration result has a notable decrease when compared to the 





Figure 4.13. The TGA Time to Peak for each cohort. Error bars represent mean with standard error of the mean. * 
represents statistical significance p<0.05, ** represents statistical significance p<0.01, *** represents statistical 
significance p<0.001 
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apixaban were not notably decreased for the PH (Table 4.14). There was a marked 
decrease in the PH for the peak concentration compared to the trough concentration 
for rivaroxaban (p<0.001 Table 4.14), but this was not seen for either apixaban doses 


































































































139.71 72.7* 101.58 71.97* 93 95.83* 89.57 




- 234.94 27.095 86.77 31.924 165.31 65.92 
Unpaired t-
test  
- 0.00001 0.17293 0.03236 0.17156 0.12546 0.11878 
Paired t-test - - 0.000471 - 0.10398 - 0.73501 
Table 4.14. The mean Peak height, range and drug concentration of the TGA for each cohort. p values for unpaired and 









Endogenous Thrombin Potential:  
The ETP was found to be significantly reduced with the presence of peak rivaroxaban 
concentrations when compared to the healthy controls (p<0.001 Table 4.15). Both 
apixaban doses were not found to be different from the healthy controls. The trough 
concentrations of rivaroxaban and apixaban were not notably decreased for the ETP 
(Table 4.15). There was a major reduction in the ETP for the peak concentration 
compared to the trough concentration for rivaroxaban (p<0.0001 Table 4.15), but this 
was not seen for either apixaban doses (2.5mg: p=0.67, 5mg: p=0.36 Table 4.15). 
 



































- 234.94 27.095 86.77 31.924 165.31 65.92 
t-test - 0.00016 0.59686 0.17140 0.26685 0.74804 0.77713 




Table 4.15. The mean ETP, range and drug concentration of the TGA for each cohort. p values for unpaired and paired t-tests 
are provided. Bold represents significance. * represents comparison of cohort to control 
 
Figure 4.14. The TGA Peak Height for each cohort. Error bars represent mean with standard error of the mean. * represents 
statistical significance P<0.05, *** represents statistical significance p<0.001 
 




























































































The velocity Index (VI) was found to be reduced with the presence of peak rivaroxaban 
concentrations when compared to the healthy controls (p<0.001 Table 4.16). Both 
apixaban doses were not found to be different from the healthy controls. The trough 
concentrations of rivaroxaban and apixaban were not notably decreased for the VI 
(Table 4.16). There was a notable difference in the VI for the peak concentration 
*** 
*** 
Figure 4.15. The ETP for each cohort. Error bars represent mean with standard error of the mean., *** represents 
statistical significance p<0.001 
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compared to the trough concentration for rivaroxaban (p<0.01 Table 4.16), but this 


































29.47 11.86* 18.325 14.13* 20.36 19.3* 20.63 




- 234.94 27.095 86.77 31.924 165.31 65.92 
t-test - 0.00047 0.20373 0.14590 0.43044 0.28828 0.42028 





















































































Table 4.16. The mean VI, range and drug concentration of the TGA for each cohort. p values for unpaired and paired t-




Figure 4.16. The VI for each cohort. Error bars represent mean with standard error of the mean., ** represents 
statistical significance p<0.001, *** represents statistical significance p<0.001 
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4.2 The Influences and Interferences of Obesity on Coagulation Assays  
The BMI was calculated for each participant (Weight (kgs)/Height (cms)/Height (cms) 
*10000) and the results were split into four categories which includes healthy weight, 
overweight, obese I and obese II/III. The Kruskal Wallis test, or single factor ANOVA 
was employed to evaluate if there were significant differences (α=0.05) between the 
weight groups at peak concentration. The obese II and obese III categories were 
grouped together for the analysis as both cohorts did not contain adequate sample 
numbers for individual analysis. As the apixaban 2.5mg and 5mg doses contained too 
little samples for statistical purposes, both apixaban doses were compared to act as a 





The Kruskal Wallis tests found there was significant differences between weight groups 
for the APTT assay when patients underwent rivaroxaban therapy (p<0.01 Tables 4.17), 
Coagulation 
Assays 






DRVVT TAT PF1+2 
Healthy  0.5191 0.2392 0.4224 0.3053 0.3679 0.4302 0.0080 0.3187 0.8027 0.1081 0.4171 
Rivaroxaban 0.2668 0.0099 0.7185 0.3165 0.3882 0.4665 0.2821 0.3962 0.7767 0.4402 0.4088 
Apixaban 0.7952 0.2047 0.5514 0.1158 0.2839 0.3274 0.8159 0.2600 0.2639 0.2495 0.1964 
TGA Lag Time  Time to Peak  Peak Height  ETP  Velocity Index  
Healthy 0.5050 0.6646 0.4860 0.9086 0.2919 
Rivaroxaban 0.6259 0.4077 0.4405 0.2044 0.5738 
Apixaban 0.7888 0.2842 0.5873 0.6218 0.6320 
Tables 4.17. The p values from the Kruskal Wallis tests comparing the cohorts BMI categories with each assay 
and each TGA parameter. Bold numbers are significantly different between weight groups (p<0.05).  
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and for the free protein S assay for the healthy controls (p<0.01 Tables 4.17). The 
apixaban cohort and majority of the rivaroxaban and healthy controls did not measure 
a significant difference between the weight groups for the other assays, including all 

























Rivaroxaban APTT compared with Cohort BMI
Healthy Controls Rivaroxaban
Figure 4.13. The Mean APTT level per each weight category between Healthy controls and rivaroxaban. Error bars 
represent standard error of the mean.  
 
Figure 4.14. The mean Protein S level per each weight category for the healthy cohort. n= Number of participants within 




















Protein S levels compared with control BMI 




5.1 Effects of Rivaroxaban and Apixaban on Coagulation Assays 
This study hypothesised that the DOACs rivaroxaban and apixaban exert a dose dependent 
effect on coagulation parameters. To validate or refute this claim we tested three aims which 
included; characterising and comparing the effects of rivaroxaban and apixaban on routine 
coagulation parameters, determining whether samples taken at trough levels have less 
interference than at peak levels, and determining the effects obesity has on coagulation 
parameters and its interferences on FXa inhibitor treated samples. The strength of this study is 
that we have matching real world patients instead of the commonly used normal pooled 
spiked plasma samples, or in silico simulations as used in previous studies. Our study has been 
effective as we confirm that rivaroxaban and apixaban revealed statistically significant 
differences for the PT, APTT, DRVVT, fibrinogen (2.5mg apixaban), and TGA assays. There were 
differences in the magnitude of influence from rivaroxaban as peak results were more potent 
than trough doses for the PT, APTT, DRVVT and TG assays. There were also significant 
differences between the influence of trough apixaban concentration to peak with the PT, 
DRVVT, TG assays at 2.5mg and 5mg doses, APTT assay at 5mg concentrations only and the 
fibrinogen assay at 2.5mg only.  Finally, the influence of obesity on DOAC patient samples 
when measured was found to be non-significant with obesity exerting no effects on these 
parameters for the apixaban, rivaroxaban (apart from the APTT assay), and the controls 
excluding the free PS assay.  
5.1.1 DOAC Effects on Coagulation Panel. 
The prothrombin time assay is routinely used within a diagnostic laboratory for the monitoring 
of VKA and has been reported to be prolonged by the presence of rivaroxaban in a linear 
concentration dependent manner, depending on the thromboplastin reagents, instruments, 
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and data analysis used (81-83). Earlier papers have reported that rivaroxaban has predictable, 
dose dependent pharmacokinetics which can be assessed using the prothrombin time, but not 
by the common international normalised ratio (INR) as the INR was developed specifically for 
VKAs (82). Our results found that peak levels (234.94 ng/ml) of rivaroxaban significantly 
prolongs the prothrombin time, which is in conjunction with the literature. It has been 
suggested that rivaroxaban may interfere with PT-based factor activity assays (FVII, FX, FV, and 
FII) which leads to decrease factor levels and a prolonged prothrombin time with increasing 
rivaroxaban concentration (84,85,86).  
Apixaban has not shown significant differences between peak concentration (2.5mg: 
86.77ng/ml 5mg: 165.31ng/ml) samples and the controls, but there was an effect on the assay 
as significant differences in PT between peak and trough apixaban doses were reported. These 
differences are found to be in conjugation with other studies which state that apixaban does 
produce an increase in clotting times, but such a small influence that the PT would still be 
regarded as normal at peak levels of apixaban (87,88). The reason for this prolongation is due 
to apixaban having a minor influence with the same PT based clotting factors as rivaroxaban 
due to the similar pharmacokinetics and pharmacodynamics. However, the PT assay is not 
sensitive enough to detect peak levels of apixaban (89) from the controls which support our 
findings. 
The APTT assay is affected by the presence of rivaroxaban as there was significantly prolonged 
clotting time at peak concentrations when compared to the healthy controls. There were also 
substantial differences between the peak and trough rivaroxaban clotting times, but the 
trough was not found to be different to the controls which would suggest that only higher 
concentrations adequately prolong the assay. This is reflected within the literature with 
research stating that rivaroxaban caused prolonged APTT results when at peak dosage (58). 
Interestingly, the peak apixaban cohorts did not produce a considerable influence on the assay 
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when compared to the normal, but there was an effect present as there was a notable 
difference between peak and trough concentrations for the 5mg sub-cohort. This difference 
would suggest that apixaban affected the APTT assay, but at such a small influence that the 
APTT result can be regarded as normal at peak levels, similar to apixaban’s effect on the PT 
assay (87,88).  
The TCT, fibrinogen and D-dimer assays were not influenced by the presence of the direct FXa 
inhibitors when peak and trough concentrations were compared to the control cohort. The D-
dimer and TCT assays were both unaffected to the presence of either rivaroxaban or apixaban 
concentrations. This is seen in the literature as both DOACs have failed to prolong the TCT or 
the D-dimer assays (85, 90, 91). The literature has also stated that the Clauss fibrinogen assay 
is not affected by the presence of rivaroxaban which is consistent with our findings (90), but 
there is an absence of data regarding apixaban’s effect on the fibrinogen assay at trough and 
peak. Apixaban has not been found to be an influence on the Clauss fibrinogen assay when 
compared to the normal controls in this study, but there was a minor decrease in fibrinogen 
levels for the 2.5mg apixaban peak sub-cohort compared to the trough sub-cohort. This 
difference could be due to the low sample number per sub-cohort (n=11) and/or the influence 
of one patient diagnosed with dysfibrinogenaemia in their medical history. Whilst there was a 
statistical difference with the 2.5mg apixaban cohort it does not equate to a clinically relevant 
difference and so it can be concluded that the fibrinogen assay is not significantly affected by 
apixaban or rivaroxaban.   
5.1.2 Thrombophilia Panel 
The thrombophilia panel consists of the antithrombin III, free protein S, protein C, and the 
DRVVT assays which measure the presence of an individual’s anticoagulant functions. The ATIII 
(Berichrom® Antithrombin III (A)), PS (Innovance® Free PS Ag), and PC (Berichrom® Protein C) 
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assays were not found to be influenced by any means by the presence of rivaroxaban or 
apixaban at peak or trough concentrations within this study. 
 A study by Gosslin et al. (2016) regarding free PS assays has stated that the trough levels of 
rivaroxaban (35ng/ml) and peak doses of apixaban (471ng/ml) leads to increased PS 
expression to clot based free PS assays using StaClot PS reagents (58). Another study by Mani 
et al. (2012) found that there were significant differences using free PS clotting assays, but did 
not find statistical significance using an immune-turbidimetric method or reagents (90). Our 
results are in line with this finding as the free PS assay used was an immune-turbidimetric 
method with the use of two different monoclonal antibodies for free PS, not a clotting based 
method. The immune-turbidimetric method is not found to be affected by rivaroxaban or 
apixaban, which would suggest that rivaroxaban and apixaban does not directly affect free PS.  
There was however an interesting observation of the free PS assay results which contained 
three patients with unusually low free PS concentration in the rivaroxaban trough cohort. Two 
of these patients experienced a tremendous rise in their free PS levels at peak rivaroxaban 
concentration. The third patient was diagnosed with a protein S deficiency, anticardiolipin, and 
B2 glycoproteins and predictably did not increase their free PS levels at peak. The causation of 
this rise in free PS levels is not known, but it can be due to three potential causes. The first 
would the possibility of a pipetting error for the assay that caused a low free PS to be recorded 
in the samples. This would be supported by the drastic difference between peak and trough PS 
concentrations. Weight could also be a factor as obesity does interfere with free protein S 
levels (92), but both patients measured healthy BMIs. The final cause could be the effect of 
rivaroxaban supporting free protein S generation, or helping to reduce PS inhibition, by 
inhibiting thrombin generation. Reduced coagulation could place less strain on the production 
of free PS which could lead to increased levels of the natural anticoagulant. This could lead to 
patients with free PS deficiencies gaining normal PS levels during rivaroxaban treatment. 
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However, the TAT and PF1+2 results for these two patients are not abnormal which does not 
suggest DOAC influences, so these results need to be confirmed as time restraints prevented 
further investigation for this study.  
The protein C assay is similarly reported as the same as the free PS assay, as peak levels of 
rivaroxaban (250ng/ml) and apixaban (>750ng/ml) caused falsely elevated clot based PC assays 
(58). However, both Gosslin et al. and Mani et al. studies have employed chromogenic 
methods for the PC assay and have reported no effects on the results by rivaroxaban or 
apixaban at peak or trough concentrations (58,90). Our results have also found no notable 
differences between the rivaroxaban or apixaban cohorts with the healthy controls regarding 
the PC assay. 
The ATIII assay was not found to be influenced by the presence of rivaroxaban or apixaban 
using the Berichrom ATIII assay by this study, but this assay has been reported to be falsely 
increased by both apixaban and rivaroxaban (58). Another study that compared three various 
ATIII reagents with rivaroxaban however, stated that the Berichrom assay is not affected by 
the presence of rivaroxaban (88). The article states that ATIII assays can only be influenced by 
rivaroxaban if the type enzyme used for the reaction is susceptible to anti-Xa influence. 
Reagents using bovine thrombin, such as the Berichrom assay, or human thrombin are 
unaffected, but assays using FXa-based amidolytic activity will be inhibited in a dose-
dependent manner by rivaroxaban (91). It was suggested by Hillarp et al. (2011) that 
rivaroxaban may raise the activity of ATIII during the screening of the thrombophilia panel, 
which may result in a missed diagnosis of inherited thrombophilia if the patient is on 
rivaroxaban therapy (91). Rivaroxaban patient samples undergoing ATIII assays need to be 
taken cautiously as different results will be generated based on the reagents used. However, 
using a thrombin-based assay over a FXa assay would lead to a reliable measurement of ATIII 
for rivaroxaban treated samples, as found by this study.  
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Apixaban may be used along the same principals as rivaroxaban due to their matching 
similarities but most of the encompassing studies on ATIII assays have not looked at the effects 
of apixaban in their analysis, and requires further data for validation. Our study however had 
found no effect on the ATIII assay by peak or trough concentrations of 2.5mg or 5mg tablets of 
apixaban, so it can be suggested that apixaban does not directly affect ATIII.  
Whilst the PC, free PS and ATIII assays have not shown notable differences between the 
controls and drug cohorts at peak or trough, it can be noted that some assays will be 
influenced based on the method and reagents used. For example, the clotting methods that 
rely on activating factors II, V, VII, X, VIII, IX, XI, or XII have been found to be mildly influenced 
by rivaroxaban, which would in turn manipulate the result of the assay (90). The use of direct 
immune-turbiditic or chromogenic methods however are not affected which suggests that the 
PC, free PS and ATIII proteins are not directly affected by the FXa-inhibitors rivaroxaban and 
apixaban.   
The DRVVT assay was found to be heavily influenced by the presence of rivaroxaban at both 
peak and trough concentration with the normalised DRVVT ratio increasing with rising drug 
concentration. This result is well documented within the literature as the DRVVT ratio is 
reliably increased from rivaroxaban (59,60,61,90,93,94). The increase in the DRVVT ratio has 
led to the prevalence of false positives for the presence of LA at peak concentrations which 
would be lead to the false diagnosis of LA in a LA negative patient. The earlier literature 
suggests using the DRVVT for trough samples as an acceptable procedure to test for LA for a 
patient on DOACs, but we have found that trough concentrations of rivaroxaban greatly 
influence the assay, leading to false positives, a result that is mirrored in only recent literature 
(56). 
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Apixaban has been shown to influence the DRVVT at peak concentrations for the 2.5mg and 
5mg sub-cohorts, and at trough for the 5mg sub-cohort. Whilst there was a substantial effect, 
it is less than half the effect of rivaroxaban. Apixaban’s potency is displayed in our study as the 
lowest apixaban concentration, the 2.5mg trough sub-cohort, was not notably different when 
compared to the healthy controls. This result has been supported by the Hillarp et al. (2014) 
study which has shown that apixaban does affect the DRVVT assay at high concentrations, but 
has suggested that since the overall influence is smaller than rivaroxaban, apixaban cannot 
cause false positive results (62). From our study, we have recorded that apixaban peak levels 
reached past the DRVVT positive ratio threshold of 1.25 for 5 apixaban samples at peak and 4 
at trough. Our results would suggest that apixaban does contain the potential to cause false 
positive results using the DRVVT assay. The Ratzinger et al. (2016) study on trough apixaban 
influences also reported false positives at 150ng/ml which further reinforced our results (56). 
5.1.3 Non-Routine Assays (TAT, PF1+2, and TGA) 
The thrombin/antithrombin complex and prothrombin fragments 1+2 ELISA assays quantitate 
the concentration of each molecule present within citrated plasma. The results have reported 
that rivaroxaban and apixaban did not influence these assays when compared to the controls. 
This is surprising as DOACs binding to FXa decreases the quantity of prothrombin converting 
into thrombin, which would in turn decrease the levels of TAT and PF1+2 produced within the 
system, but this reduction is not seen. The literature is scarce on information on the effects of 
rivaroxaban on these assays with three studies stating the effects on the TAT assay and two on 
the PF1+2. Two studies stated that the TAT assay is not significantly increased by the presence 
of rivaroxaban with patients with heart failure (95,96). However, a recent study by Horinaka et 
al. (2017) stated that 15mg rivaroxaban has caused a significant decrease in the amount of 
PF1+2 and TAT found in patient samples (97).  
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It should also be noted that the TAT assay in our experiment contains noticeable outliers in 
both the rivaroxaban and apixaban cohorts, but this burst of TAT may be due to TAT activation 
caused during sample collection and/or processing (98). There are also patients in both cohorts 
that have Factor V Leiden in their medical histories that would have affected the assay by 
increasing TAT levels (99) and produced the outliers. 
Another study has stated that rivaroxaban patient’s PF1+2 results are significantly higher when 
compared to warfarin treated patients, but interestingly does not differ in its influence from 
peak to trough concentrations (100). It has been suggested that the reason for the lack of 
difference between peak and trough may be the short half-life of the PF1+2 fragment (90 
minutes), or the influence of other anticoagulants such as PC, PS, AT, or TFPI (100). As our 
study enlisted patients already on rivaroxaban therapy, the TAT and PF1+2 concentration of 
the patients before rivaroxaban therapy, or on warfarin, was unknown and would require a 
suitable follow up trial. We do however have the difference between peak and trough doses 
which was found to not be significantly different, as reinforced in the literature (100), and the 
comparisons of peak with the control cohorts which was also not significantly different. 
Apixaban was found to not cause a notable difference in TAT between the normal cohort at 
peak or trough in our findings, which is supported by a study by Nagao et al. (2017) (96). 
Apixaban also did not cause a major difference for the PF1+2 assay at peak or trough for both 
doses compared to the controls, or have differences between peak and trough. There are 
currently no other accounts of apixaban’s influence on the PF1+2 so the results should to be 
validated. 
The five parameters of the TGA were found to all be influenced by rivaroxaban, with apixaban 
also influencing the tPeak and PH. The rivaroxaban cohort at peak concentration prolonged the 
lag time and tPeak, decreased the ETP and PH, and has slowed the thrombin generation 
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process by decreasing the VI. It can be shown as well that the patients experience a 
considerably larger effect on their TG at peak than at the trough, suggesting the effects of 
rivaroxaban on the TGA is dose dependent. The literature supports this as a study found 
similar prolongations and decreases with the TGA parameters using the CAT analyser with 
increasing doses (101).  
Apixaban in this study has also shown to affect the TGA assay but not to the same extent to 
rivaroxaban. The drug produced a noticeable difference in PH and tPeak parameters for the 
peak 2.5mg tablets when compared to the controls, but not for the 5mg apixaban peak tablets. 
This is unexpected as logic would dictate that the higher the concentration of apixaban, the 
higher the influence on the assay. The peak 5mg apixaban cohort contained a longer tPeak and 
lower PH but it was not considerably different from the controls, as there are outliers pulling 
the data towards the normal range which results in the data to become insignificant. A study 
looking at the effects of apixaban on the TGA parameters have stated that apixaban influences 
all parameters in a similar fashion to rivaroxaban (101), but we have found only influence of 
the PH and tPeak with this study. Prolongations of individual TGA parameters have been found 
before due to variations in coagulation factor proteins (102), but the study participants did not 
have previous factor deficiencies recorded in their medical histories. As the TGA parameters 
are all linked to produce a thrombogram it can be suggested that if one parameter is affected, 
all the others are affected as well when taking rivaroxaban. Whilst the lag time, ETP, and VI 
were not statistically different with the patient apixaban concentrations in this study, it can be 
speculated that all parameters can be significantly influenced at higher apixaban doses.  
5.2 Effects of Weight  
The effects of weight on DOAC pharmacodynamics has been questioned by a series of case 
studies on the effects of obesity with the FII inhibitor dabigatran (77-79). With most papers 
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omitting the data on the effects of apixaban and rivaroxaban between BMI categories, this 
study was aimed to evaluate if there was a relationship with weight and DOACs by measuring 
the effects on coagulation assays within each cohort. Using the Kruskal Wallis test we have 
evaluated that apixabans influence on coagulation or TG is not influenced by the patient’s BMI. 
Weight did not influence the rivaroxaban cohort, apart from the APTT assay which has 
recorded a significant increase in clotting time with patients with larger BMIs. The healthy 
control cohort contained no significant differences in results by weight, apart from the free 
protein S assay that contained higher free PS levels in obese controls.   
The APTT assay under the influence of rivaroxaban was found to have significant differences 
between BMI groups with the healthy BMI group containing on average a APTT of 31.58 
seconds compared to the combined obese II and obese III cohort average of 36.64 seconds. 
There could be several reasons for this discrepancy with the most obvious cause being the 
differences of rivaroxaban concentrations between each of the groups. The drug levels for 
each of the groups varies with the averages for healthy (235.94ng/ml), overweight 
(157.24ng/ml), obese I (247.15ng/ml), and obese II/III (268 ng/ml) with a positive trend of 
increased BMI with increased drug. The use of VTE patients adds additional variability on the 
assay, as many patients will have several factors or influences acting on their APTT such as 
their age, genetics, haematocrit levels, or the timing and method of sample collection and 
storage (103).  
There could also be physiological reasons for the differences between the healthy BMI and 
obesity for the APTT assay, with the literature stating that acquired obesity increases the 
activities of fibrinogen and the intrinsic factors FIX, FXI, FXII, and PAI-1 (104). However, as 
obesity would increase the amount of intrinsic clotting factors present, it would be expected 
that the APTT would be shortened, not prolonged as found within this study and that the 
fibrinogen levels would be elevated, which was also not found. Whilst there is currently no 
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published data for the effect of peak concentrations of rivaroxaban on the APTT of VTE obese 
vs lower BMI patients, this study would warrant further investigation on to the differences of 
rivaroxaban between obese and healthy APTT times.  
The other assay that found significant differences between the BMI groups was the free 
protein S for the control cohort. The literature does suggest that obesity influences free 
protein S levels as a paper by Murakami et al. (2007) states that free protein S levels are 
drastically reduced in obese patients after weight loss (105). Another study by Pintao et al. 
(2013) has found that protein S levels were found to be higher in overweight/obese 
participants than healthy participants in their study (92). The free protein S assay is affected by 
the participant’s BMI with our study which mirrors the literature. However, our result is to be 
taken cautiously as there are several analytical limitations to our study. The first is the low and 
uneven sample numbers per BMI groups as there are ten samples within the overweight 
cohort compared to only four samples in the obese I, II, and III cohorts combined. As the 
control cohort was gathered from volunteers, previous medical histories were not acquired, so 
it is possible that a volunteer may not be healthy or would contain medical/lifestyle factors 
that would influence their free protein S levels, or the free PS assay itself. Another note is that 
the apixaban and rivaroxaban cohorts did not disclose significance between their results 
between their BMI groups for the free PS assay. The free PS assay is affected by weight so it is 
would be expected that other cohorts would follow suit, but this was not seen. 
5.3 Comparison of Rivaroxaban and Apixaban Pharmacodynamics   
Apixaban and rivaroxaban are selective, reversible direct FXa inhibitors that influence the same 
assays, but exert different pharmacodynamics using the same method of action. The 
therapeutic doses, efficacy, molecular masses (459.5 Da for apixaban, 436 Da for rivaroxaban 
(62)), and the pharmacokinetics of the two DOACs are comparable but Jourdi et al. (2015) has 
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revealed that the effects of the two drugs are not equal (89). The study stated that a 
discrepancy between drugs is due to a difference in the overall rates of association and 
dissociation to FXa which leads to difficulty in detecting apixaban. Jourdi et al. (2015) found 
that FXa had a higher affinity for rivaroxaban than apixaban, which results in rivaroxaban 
neutralising FXa four-fold more rapidly than apixaban (89). When comparing drugs using in 
silico PT and TG assays it was calculated that the PT is not sensitive enough to detect 
concentrations of apixaban, but can be used for rivaroxaban. The effect caused by rivaroxaban 
on the PT assay also depends on the level of thromboplastin tissue factor (TF) content as 
decreasing TF can increase the assay sensitivity (89). The TGA revealed all parameters in their 
study was affected by the two drugs, but stated that rivaroxaban is more potent than apixaban 
which led to a far greater rivaroxaban influence than apixaban on the TGA (89).  
The study does not address however if the trough concentrations of rivaroxaban and apixaban 
have less of an influence than at peak. From our study, there are dose dependent responses to 
the four assays, with greater deviations from the normal at the peak concentrations than at 
trough for both rivaroxaban and apixaban.  
As rivaroxaban has a 4-fold increase of rate activity compared to apixaban it can be speculated 
that rivaroxaban produces a rapid influence on an assay at peak but drops to a lesser influence 
at trough before the next dose. This is supported by the rivaroxaban’s short half-life of 7-11 
hours (106). After peak, 3-4 hours after ingestion, there is rapid decrease in rivaroxaban 
plasma concentrations followed by approximately a 4-hour period of trough concentrations 
(107) before the next dose, which highlights the major difference between the peak and 
trough effects reported in this study.  
The onset of apixaban activity can be described as more of a gradual rise that stays steady for 
longer before declining at trough. Apixaban contains a half-life of 10-14 hours with tablets 
administered at 12 hours intervals. As the time between doses had been decreased the 
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average trough level increases and is maintained at a steadier state throughout the duration 
before next the dose (105). These differences are also due to the dosing regimen of the two 
drugs as 20mg rivaroxaban is administered once a day, whilst apixaban is administered twice 
daily. Our data reflects this as the average difference between peak and trough rivaroxaban 
concentration was 207ng/ml, whilst 2.5mg and 5mg apixaban had an average difference of 
only 55ng/ml and 98ng/ml respectively. This would suggest that rivaroxaban has a greater 
influence at peak than at trough, whilst apixaban has a noticeably smaller influence between 
peak and trough.  
The difference in peak over trough influence is highlighted by looking at the mean percentage 
difference between the rivaroxaban and the two apixaban cohorts. Mean percentage 
difference was used as individual paired samples will experience different variations 
depending on the drug level and patients baseline level.  The rivaroxaban PT, APTT and DRVVT 
ratio mean percentage difference was 18.71%, 15.6% and 24.6% respectively. Figures 5.1 
















































































































































Apixaban on the other hand displays a steadier state which can be seen when comparing the 
mean percentage difference of the PT, APPT, and DRVVT assays. The mean percentage 
differences for the assays was 3.33%, 1.62%, and 2.37% for the 2.5mg apixaban cohort, and 
5.20%, 3.95%, and 3.72% for the 5mg apixaban cohort respectively. These graphs highlight the 
effects of bi-daily administration of apixaban over the effects of daily rivaroxaban on peak and 
trough.  
Figures 5.1. Results of peak and trough rivaroxaban for the PT, APTT, and DRVVT assays. Error bars represent mean with 
standard error of the mean. Black lines highlight differences between peak and trough means. 
 
Figures 5.2. Results of peak and trough apixaban cohorts for the PT, APTT, and DRVVT assays. Error bars represent mean 
with standard error of the mean. Black lines highlight differences between peak and trough means. 
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 5.4 Limitations of Study Design 
We have successfully investigated the effects of apixaban and rivaroxaban on coagulation 
parameters in this study but there are a series of limitations that need to be addressed.  
The three cohorts are limited by small sample sizes as it would be desirable to obtain larger 
numbers with at least 30 participants, especially with the 2.5mg and 5mg apixaban sub-cohorts 
as these groups only contain 10-11 participants. The healthy control cohort is limited by their 
unknown medical history and lifestyle influences, as more thorough documented controls 
would strength the normal ranges and reduce outliers. It should also be noted that the 
samples used within this study were real world patients, and not spiked normal pooled plasma, 
which leads to various levels for peak and trough as different participants experience different 
rates of pharmacodynamics. The peak sample collection time is a limitation as some samples 
were taken 10 minutes early or late, than exactly 3 hours which may influence the results.  
When dealing with weight it would have been desirable to gather waist circumference in 
addition to BMI, as BMI has been criticised for being only an estimation of adiposity, and does 
not consider the differences in muscle mass or other lifestyle influences (108). The patient 
cohort should be fully representative of the weight spectrum with adequate numbers of 
participants in each BMI cohort especially with the obese BMI groups in the control cohort.  
A key limitation found with this study would be the use of only single runs for the TGA, 
coagulation, and thrombophilia panels per sample, and not using duplicate or triplicate runs. 
The use of duplicate run would have increased accuracy and led to greater strength and 
statistical confidence to the results. It should be noted that the PF1+2 and TAT assays were the 
only assays performed in duplicate.  
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5.5 Summary and Future directions 
This study has validated the hypothesis that the DOACs rivaroxaban and apixaban exert a dose 
dependent effect on coagulation parameters and thrombin generation. 
The study has demonstrated that the direct acting oral anticoagulants rivaroxaban and 
apixaban have shown to affect the PT, APTT, DRVVT, and TG assays and do not affect the 
fibrinogen, D-dimers, TCT, ATIII, PC, free PS, TAT or the PF1+2 assays. It can be shown that 
rivaroxaban contains a more potent effect than apixaban as rivaroxaban is significantly 
different from the normal control cohort at peak drug concentrations for the PT, APTT, DRVVT, 
and TGA assays, as well as differences between peak and trough concentrations. Apixaban was 
shown to affect the PT and APTT assays between peak and trough but was not significant from 
the normal controls. Apixaban also affects the DRVVT and PH, tPeak parameters for the TGA 
for the 2.5mg dosage sub-cohort, but interestingly not for the 5mg apixaban sub-cohort.  
An aim of this study was investigating if peak concentrations influence coagulation assays 
more than trough, which we have shown to be correct for affected assays. Rivaroxaban has 
major differences between its peak and trough, whereas apixaban has more of a steady state 
with slight differences between peak and trough. These differences are due to the different 
pharmacokinetics and pharmacodynamics of rivaroxaban and apixaban, especially the half-life 
and daily/bi-daily dosage routine. It is noteworthy to add that whilst the trough concentration 
has a considerably less of an effect than the peak, there is still an influence on these assays by 
the DOACs and results are manipulated at trough. 
The final consideration of the study was the effect of weight, especially obesity, on rivaroxaban 
and apixaban influence. The effects of the weight on the assays regarding drug influence was 
found to be insignificant for all assays and cohorts except for the APTT for rivaroxaban, and the 
free PS assay for the healthy controls. Both results are subject to low, disproportioned sample 
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sizes and patient and drug variability, but both results are supported by the literature and 
other studies (92,103,104). 
This study has shown promising results in the interpretation of coagulation and thrombin 
generation assays. The routine PT and APTT assays are both affected by rivaroxaban and 
apixaban which is important for clinicians to know during emergency monitoring. The effects 
of apixaban is underreported in the literature so this study has enhanced our understanding of 
the interpretation of apixaban’s influences. The effects of the DRVVT is well reported to be 
influenced by rivaroxaban but this study has displayed direct effects on the assay with 
apixaban. The TGA was also affected by rivaroxaban and apixaban by our findings but differ in 
their scope of influence. The effects of weight on DOAC efficiency was found to be insignificant 
for all but two assays. 
The future direction of this study would be to expand the cohort to validate our findings and 
should also expand the range of assays used, particularly the inclusion of individual clotting 
factors and the TVT/ECT assays. The inclusion of snake venoms such as the TVT/ECT could be 
seen as an alternative LA assay to the DRVVT due to the venoms acting independently from 
phospholipids, FVa, FVIIa, and FXa, and so would not be affected by DOACs. Larger cohorts will 
also provide further validation on the effects of rivaroxaban and apixaban on the DRVVT and 
TG assays. As assays are influenced depending on the methods and reagents used, a future 
study with expanded assays should contain several different commercial reagents per assay to 
see which are affected by DOACs and which are not. Future studies may be able to build a 
reliable series of minimal or unaffected coagulation tests for emergency monitoring of DOAC 
patients. With the advancements of rivaroxaban and apixaban characterisation at peak and 
trough, the treatment of VTE can be improved and can improve the clinical outcomes for 
patients undergoing this therapy and improve DOAC management and monitoring.  






The following abbreviations are used in this thesis. 
• (APTT):   Activated partial thromboplastin time  
• (ATIII):   Antithrombin III levels  
• (BMI):   Body Mass Index  
• (CAT):   Calibrated automated thrombogram  
• (DIC):   Disseminated intravascular coagulation  
• (DOACs):  Direct acting oral anticoagulant drugs  
• (DRVVT):  Dilute Russell’s viper venom time 
• (DVT):   Deep Vein Thrombosis  
• (ECT):   Ecarin clotting time 
• (ELISA):   Enzyme-linked immunosorbent assay  
• (ETP):   Endogenous Thrombin Potential  
• (PF1+2):  Prothrombin fragments 1+2  
• (INR):   International Normalised Ratio 
• (ISI):   International sensitivity index 
• (LA):   Lupus anticoagulant  
• (NOACs):  Novel oral anticoagulants 
• (PH):   Peak Height  
• (PPP):   Platelet poor plasma  
• (PT):   Prothrombin time   
• (TAT):   Thrombin/anti-thrombin complexes  
• (TCT):   Thrombin clotting time  
• (TF):   Tissue Factor 
• (tPeak):   Time to Peak 
• (TVT):   Taipan venom time  
• (VKA):   Vitamin K Antagonist  
• (VTE):    Venous thromboembolism 
• (VI):   Velocity index 
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